Antibodies Clinical Trials

All Categories Medications / Interventions » Aa » Antibodies

Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody

Condition: Cytomegalovirus Infections
Interventions: Biological: TCN-202; Biological: Placebo
Sponsors: Theraclone Sciences, Inc.; Theraclone Sciences, Inc.
Recruiting - verified May 2012
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation

Condition: End Stage Renal Disease (ESRD)
Intervention: Drug: Tocilizumab
Sponsors: Cedars-Sinai Medical Center; Cedars-Sinai Medical Center
Not yet recruiting - verified May 2012
Brentuximab Vedotin for Steroid Refractory GvHD

Condition: Graft vs. Host Disease
Intervention: Drug: Brentuximab Vedotin
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Not yet recruiting - verified May 2012
Safety Study of FluMist With and Without Ampligen

Condition: Influenza, Human
Interventions: Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Poly I:Poly C12U; Drug: FluMist + Placebo
Sponsors: Hemispherx Biopharma; Hemispherx Biopharma
Recruiting - verified May 2012
ch14.18 Pharmacokinetic Study in High-risk Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: ch14.18 -NCI; Biological: ch14.18-UTC; Biological: Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF); Biological: Aldesleukin (IL-2); Drug: Isotretinoin
Sponsors: United Therapeutics; United Therapeutics
Not yet recruiting - verified May 2012
Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

Conditions: Brain Neoplasms; Central Nervous System Neoplasms
Interventions: Drug: TPI287; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Archer Biosciences, Inc.
Not yet recruiting - verified April 2012
International Guillain-Barré Syndrome Outcome Study

Conditions: Guillain-Barré Syndrome; Miller Fisher Syndrome
Intervention:
Sponsors: Erasmus Medical Center; Erasmus Medical Center
Recruiting - verified May 2012
A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: Humanized anti-GD2 antibody; Drug: Chemotherapy; Other: Cytokines; Biological: Natural killer cells
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Non-Invasive Biomarkers For Early Detection Of Lung Cancers

Condition: Lung Cancer
Intervention:
Sponsors: Baptist Cancer Institute; Douglas W. Johnson MD, FACR
Recruiting - verified April 2012
EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

Condition: Crohns Disease
Intervention: Drug: Certolizumab
Sponsors: Baylor College of Medicine; Baylor College of Medicine; UCB, Inc.
Recruiting - verified April 2012
Induction Chemotherapy w/ABVD Followed by Brentuximab Vedotin Consolidation in Newly Diagnosed, Non-Bulky Stage I/II Hodgkin Lymphoma

Condition: Hodgkin Lymphoma, Adult
Interventions: Drug: Brentuximab vedotin; Drug: ABVD Induction
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Seattle Genetics, Inc.
Recruiting - verified May 2012
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors

Condition: Solid Tumors
Intervention: Biological: MEDI0639
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Evaluation of TRC105 In The Treatment Of Recurrent Glioblastoma After Prior Antiangiogenic Therapy (Including Anti-VEGF Therapy)

Conditions: Glioblastoma; Glioblastoma Multiforme
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Not yet recruiting - verified May 2012
Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Condition: Advanced Gastrointestinal Malignancies
Intervention: Drug: MLN0264
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
A Double-Blind, Placebo Controlled Study of Intravenous Immunoglobulin for HIV-Associated Myelopathy

Condition: HIV-associated Myelopathy
Interventions: Drug: Intravenous Immunoglobulin; Drug: Placebo
Sponsors: Mount Sinai School of Medicine; David M. Simpson; CSL Behring
Recruiting - verified March 2012
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma

Conditions: Primary Cutaneous Anaplastic Large Cell Lymphoma,; Mycosis Fungoides
Interventions: Drug: Brentuximab Vedotin; Drug: Methotrexate or Bexarotene
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.; Seattle Genetics, Inc.
Recruiting - verified May 2012
Concurrent Ipilimumab and Stereotactic Ablative Radiation Therapy (SART) for Oligometastatic But Unresectable Melanoma

Condition: Melanoma
Interventions: Drug: Ipilimumab; Radiation: Stereotactic Ablative Radiosurgery (SART)
Sponsors: Comprehensive Cancer Centers of Nevada; Wolfram Samlowski; Comprehensive Cancer Centers of Nevada
Not yet recruiting - verified April 2012
Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast Cancer

Condition: Breast Neoplasms
Interventions: Drug: lapatinib ditosylate; Biological: trastuzumab
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Not yet recruiting - verified March 2012
Multi-Drug Desensitization Protocol for Heart Transplant Candidates

Conditions: Alloantibodies; Heart Transplantation; Immunologic Memory
Intervention: Drug: Bortezomib, Thymoglobulin, (rATG), Rituximab, Gamimune N, (IVIG), Plasmapheresis (Multidrug Protocol)
Sponsors: Providence Health & Services; Providence Health & Services
Not yet recruiting - verified May 2012
Bevacizumab, Temsirolimus, Valproic Acid, Cetuximab

Condition: Advanced Cancers
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Valproic Acid; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis

Conditions: Scalp Psoriasis; Plaque Psoriasis
Interventions: Drug: Ustekinumab; Drug: Placebo
Sponsors: Yamauchi, Paul Steven, M.D., Ph.D.; Paul Steven Yamauchi, MD, PhD; Janssen Services, LLC
Not yet recruiting - verified March 2012
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)

Conditions: Chronic Inflammatory Demyelinating Polyneuropathy; Polyradiculoneuropathy
Interventions: Biological: IgPro20; Biological: Placebo
Sponsors: CSL Behring; CSL Behring; Parexel
Recruiting - verified March 2012
A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Condition: Psoriasis
Interventions: Drug: Ustekinumab 45 mg; Drug: Ustekinumab 90 mg; Drug: Placebo
Sponsors: Janssen Biotech, Inc.; Janssen Biotech, Inc.
Recruiting - verified May 2012
Pediatric Arthritis Study of Certolizumab Pegol

Condition: Juvenile Idiopathic Arthritis (JIA)
Intervention: Drug: Certolizumab Pegol (CZP)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Correlation of Donor-specific Anti-endothelial Cells

Condition: Living-Donor Kidney Transplants
Intervention:
Sponsors: Northwestern University; Northwestern University
Recruiting - verified March 2012
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

Condition: Systemic Lupus Erythematosus
Intervention: Drug: Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2012
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: prednisone; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; Genentech
Not yet recruiting - verified March 2012
Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Promyelocytic Leukemia (M3); Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: gemtuzumab ozogamicin; Other: laboratory biomarker analysis
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Sirolimus, Tacrolimus, Anti-Thymocyte Globulin, and Rituximab in Preventing Graft-versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative; Blastic Phase Chronic Myelogenous Leukemia; Chronic Eosinophilic Leukemia; Chronic Myelomonocytic Leukemia; Chronic Neutrophilic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Essential Thrombocythemia; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Polycythemia Vera; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Progressive Hairy Cell Leukemia, Initial Treatment; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Refractory Multiple Myeloma; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Untreated Adult Acute Lymphoblastic Leukemia; Untreated Adult Acute Myeloid Leukemia; Untreated Hairy Cell Leukemia; Waldenstrom Macroglobulinemia
Interventions: Drug: sirolimus; Drug: tacrolimus; Biological: rituximab; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified October 2011
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Other: pharmacological study; Drug: tacrolimus; Drug: sirolimus; Biological: anti-thymocyte globulin; Drug: fludarabine phosphate; Drug: busulfan; Drug: bortezomib; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

Condition: Myeloma
Interventions: Drug: Lenalidomide; Drug: Bortezomib; Drug: Siltuximab; Drug: Dexamethasone; Behavioral: Questionnaires
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Janssen Services, LLC
Recruiting - verified May 2012
Erlotinib With or Without Bevacizumab in Treating Patients With Stage IV Non-Small Cell Lung Cancer With EGFR Mutations

Condition: Stage IV Non-small Cell Lung Cancer
Interventions: Drug: erlotinib; Biological: bevacizumab; Other: laboratory biomarker analysis
Sponsors: Academic and Community Cancer Research United; Academic and Community Cancer Research United
Not yet recruiting - verified February 2012
A Phase 1, Randomized, Placebo-controlled, Single-dose Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Condition: Healthy Subjects
Intervention: Drug: MEDI7814
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Interventions: Drug: Brentuximab Vedotin; Drug: Adriamycin, vinblastine, and dacarbazine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Seattle Genetics, Inc.
Recruiting - verified April 2012
Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

Condition: Waldenstrom Macroglobulinemia
Interventions: Biological: ofatumumab; Drug: bortezomib; Other: laboratory biomarker analysis
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012
Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

Condition: Autoimmune Autonomic Ganglionopathy (AAG)
Interventions: Drug: Intravenous Immunoglobulin; Drug: Intravenous Immunoglobulin
Sponsors: Beth Israel Deaconess Medical Center; Beth Israel Deaconess Medical Center; Mayo Clinic; Vanderbilt University; New York University Medical Center; The University of Texas Southwestern Medical Center; National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified January 2012
Babesia Testing in Blood Donors

Condition: Transfusion Transmitted Babesiosis
Interventions: Biological: B.microti diagnostic blood tests; Biological: B.microti diagnostic blood tests
Sponsors: Imugen; Imugen; American Red Cross; Memorial Blood Centers of Minnesota; Rhode Island Blood Center
Recruiting - verified February 2012
A Dose-Escalation Study in Participants With Advanced Cancer

Condition: Advanced Cancer
Intervention: Drug: LY2495655
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified January 2012
Phase 3 IGIV, 10% in Alzheimer´s Disease

Condition: Alzheimer´s Disease
Interventions: Biological: Immune Globulin Intravenous (Human), 10% Solution; Biological: Human albumin 0.25%
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2012
High Dose Chemotherapy and Autologous Transplant for Neuroblastoma

Condition: Neuroblastoma
Interventions: Drug: Carboplatin; Biological: Autologous stem cell infusion; Biological: Granulocyte colony stimulating factor; Radiation: Radiation therapy; Drug: Isotretinoin (13-cis-retinoic acid); Drug: Melphalan; Drug: Etoposide
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified April 2012
A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002)

Condition: Clostridium Difficile Infection
Interventions: Biological: MK-6072; Biological: MK-3415A; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
Durable Effect of PCSK9 Antibody CompARed wiTh placEbo Study (DESCARTES)

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145; Other: Placebo
Sponsors: Amgen; Amgen
Recruiting - verified January 2012
Capecitabine, Temozolomide and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors

Conditions: Gastrinoma; Glucagonoma; Insulinoma; Pancreatic Polypeptide Tumor; Recurrent Islet Cell Carcinoma; Recurrent Pancreatic Cancer; Somatostatinoma; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Drug: capecitabine; Drug: temozolomide; Biological: bevacizumab
Sponsors: Stanford University; Stanford University; National Cancer Institute (NCI)
Not yet recruiting - verified January 2012
Phase 3 Trial in Subjects With Metastatic Melanoma Comparing 3 mg/kg Ipilimumab Versus 10 mg/kg Ipilimumab

Condition: Melanoma
Interventions: Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Drug: Bendamustine
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drug (DMARD)-Naïve Adults With Early Active Rheumatoid Arthritis

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab Pegol + Methotrexate (MTX); Biological: Placebo + Methotrexate (MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Study of VGX-100 Administered Alone and Co-administered With Bevacizumab in Adult Subjects With Advanced Solid Tumors

Conditions: Neoplasms; Cancer
Interventions: Drug: VGX-100; Drug: Bevacizumab
Sponsors: Circadian Technologies Ltd.; Circadian Technologies Ltd.
Recruiting - verified March 2012
Ustekinumab Quality of Life Study

Condition: Psoriasis
Intervention: Drug: Ustekinumab
Sponsors: University of California, San Francisco; University of California, San Francisco
Not yet recruiting - verified January 2012
Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma

Condition: Hodgkin's Lymphoma
Interventions: Drug: brentuximab vedotin (SGN-35); Drug: Brentuximab Vedotin (SGN-35)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Seattle Genetics, Inc.
Recruiting - verified January 2012
90 Y-BC8-DOTA Monoclonal Antibody, Fludarabine Phosphate, and Total-Body Irradiation Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma

Conditions: Refractory Multiple Myeloma; Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: peripheral blood stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Radiation: yttrium Y 90 anti-CD45 monoclonal antibody BC8
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy

Conditions: Brain Cancer; Brain Stem Glioma
Intervention: Radiation: Radioactive iodine-labeled monoclonal antibody 8H9
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Weill Medical College of Cornell University; Johns Hopkins University School of Medicine (Data analysis only)
Recruiting - verified March 2012
Rapid Oral Test for Therapeutic Response in HIV/AIDS Patients

Condition: AIDS/HIV PROBLEM
Intervention:
Sponsors: Gaia Medical Institute; Gaia Medical Institute; AIDS Healthcare Foundation
Recruiting - verified January 2012
Study of Zevalin Versus Observation in Patients at Least 60 Yrs Old With Newly Diagnosed Diffuse Large B-cell Lymphoma in PET-negative Complete Remission After R-CHOP or R-CHOP-like Therapy

Conditions: Diffuse Large B-cell Lymphoma; Follicle Center Lymphoma
Intervention: Drug: Zevalin (ibritumomab tiuxetan)
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified April 2012
Pre-Operative, Single-Dose Ipilimumab and/or Cryoablation in Early Stage/Resectable Breast Cancer

Conditions: Breast Cancer; Invasive Adenocarcinoma of the Breast
Interventions: Procedure: Cryoablation; Biological: Ipilimumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Conditions: Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer
Intervention: Biological: Ipilimumab
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Condition: Mantle-Cell Lymphoma
Intervention: Drug: Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Sponsors: Duke University; Duke University; Spectrum Pharmaceuticals, Inc
Recruiting - verified March 2012
Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate

Condition: Rheumatoid Arthritis
Interventions: Biological: Certolizumab pegol + Methotrexate (CZP + MTX); Biological: Adalimumab + Methotrexate (ADA + MTX)
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma

Condition: Melanoma
Interventions: Drug: Sylatron; Drug: Yervoy
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; Merck
Recruiting - verified March 2012
AMG 172 First in Human Study in Patients With Kidney Cancer

Conditions: Renal Cell Adenocarcinoma; Clear Cell Renal Carcinoma; Clear Cell Renal Cell Carcinoma; Renal Cell Carcinoma
Intervention: Drug: AMG 172
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

Condition: Colorectal Cancer
Intervention: Drug: Panitumumab and bortezomib
Sponsors: Georgetown University; Georgetown University; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma

Conditions: Glioblastoma; Small Cell Glioblastoma; Giant Cell Glioblastoma; Gliosarcoma; Glioblastoma With Oligodendroglial Component; Recurrent Glioblastoma; Relapsed Glioblastoma
Interventions: Drug: Bevacizumab; Drug: Rindopepimut (CDX-110) with GM-CSF; Drug: KLH
Sponsors: Celldex Therapeutics; Celldex Therapeutics
Recruiting - verified May 2012
Safety Study of a Vaccine (DENV-1 PIV) to Prevent Dengue Disease

Condition: Dengue Fever
Interventions: Biological: DENV-1 PIV, 2.5 µg; Biological: DENV-1 PIV, 5 µg
Sponsors: U.S. Army Medical Research and Materiel Command; U.S. Army Medical Research and Materiel Command
Recruiting - verified April 2012
Study of Brentuximab Vedotin (SGN-35) in Pediatric Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Conditions: Hodgkin Lymphoma; Anaplastic Large-cell Lymphoma
Intervention: Drug: brentuximab vedotin
Sponsors: Millennium Pharmaceuticals, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2012
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: cyclophosphamide; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: vincristine sulfate; Drug: cytarabine; Procedure: autologous hematopoietic stem cell transplantation; Drug: methotrexate
Sponsors: Roswell Park Cancer Institute; Roswell Park Cancer Institute; National Comprehensive Cancer Network
Recruiting - verified April 2012
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

Condition: Primary Immunodeficiency Disorders
Interventions: Biological: Immune Globulin Infusion (Human), 10%; Biological: Recombinant human hyaluronidase
Sponsors: Baxter Healthcare Corporation; Baxter Healthcare Corporation
Recruiting - verified May 2012
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease

Conditions: Graft Versus Host Disease; Steroid Refractory GVHD; Acute GVH Disease
Intervention: Drug: Infliximab and Basiliximab as combination therapy
Sponsors: Nationwide Children's Hospital; Nationwide Children's Hospital; Ohio State University Comprehensive Cancer Center
Not yet recruiting - verified December 2011
A Study of Siltuximab (Anti- IL 6 Monoclonal Antibody) in Patients With High-risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Interventions: Drug: Siltuximab; Drug: Placebo
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified February 2012
Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Condition: Melanoma
Interventions: Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: BMS-982470 (recombinant interleukin-21); Biological: Ipilimumab; Biological: Ipilimumab; Biological: Ipilimumab
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
Observational Study of Tysabri in Early Relapsing-Remitting Multiple Sclerosis in Anti-JCV Antibody Negative Patients

Condition: Relapsing-remitting Multiple Sclerosis
Intervention:
Sponsors: Biogen Idec; Biogen Idec
Recruiting - verified May 2012
Chikungunya Virus Vaccine Trial in Healthy Adults

Conditions: Chikungunya Virus; Vaccines, Virus-like Particles; Viral Vaccines; Humoral Immunity; Chikungunya Fever
Intervention: Biological: VRC-CHKVLP059-00-VP
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified November 2011
MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.

Condition: Unresectable or Metastatic Hepatocellular Carcinoma (HCC)
Interventions: Drug: MEDI-573 (1 of 2 doses); Drug: Sorafenib
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Belimumab 200 mg SC
Sponsors: Human Genome Sciences; Human Genome Sciences; GlaxoSmithKline
Recruiting - verified May 2012
Radiolabeled Monoclonal Antibody Therapy and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Primary Refractory or Relapsed Hodgkin Lymphoma

Condition: Recurrent Adult Hodgkin Lymphoma
Interventions: Biological: basiliximab; Drug: carmustine; Drug: etoposide; Drug: cytarabine; Drug: melphalan; Other: pharmacological study; Other: laboratory biomarker analysis; Procedure: autologous hematopoietic stem cell transplantation; Biological: basiliximab; Biological: basiliximab
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Not yet recruiting - verified November 2011
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)

Conditions: Antiphospholipid Syndrome; Thrombophilia Due to Antiphospholipid Antibody; Systemic Lupus Erythematosus
Intervention: Other: Phlebotomy
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Michael D. Lockshin, MD - Hospital for Special Surgery; Jacob H. Rand, MD - Montefiore Medical Center
Recruiting - verified November 2011
Trastuzumab in Combination With AMG 479 in HER-2 Overexpressing MBC Progressing on Trastuzumab

Condition: Breast Cancer
Interventions: Drug: AMG 479; Drug: Trastuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Not yet recruiting - verified November 2011
Phase II Trial of RA-18C3 in Subjects With Moderate to Severe Acne Vulgaris

Condition: Acne Vulgaris
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012
Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

Condition: Crohn's Disease
Interventions: Drug: Placebo; Drug: Placebo; Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody); Drug: BMS-936557 (Anti-IP-10 Antibody)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified February 2012
A Study to Evaluate the Efficacy and Safety of GS-6624 Combined With Gemcitabine for Metastatic Pancreatic Adenocarcinoma

Condition: Pancreatic Cancer
Interventions: Drug: GS-6624; Drug: GS-6624; Drug: Placebo; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: Gemcitabine; Drug: GS-6624
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma

Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Splenic Marginal Zone Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: BTK inhibitor PCI-32765; Biological: rituximab; Drug: bendamustine hydrochloride; Other: pharmacogenomic studies; Other: pharmacological study; Other: laboratory biomarker analysis
Sponsors: Ohio State University Comprehensive Cancer Center; Ohio State University Comprehensive Cancer Center; Pharmacyclics
Recruiting - verified January 2012
Efficacy and Safety of GS-6624 With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Condition: Colorectal Cancer
Interventions: Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: GS-6624; Drug: FOLFIRI; Drug: Placebo; Drug: FOLFIRI
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified March 2012
Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: Blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012
Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Condition: Acute Lymphoblastic Leukemia
Intervention: Drug: blinatumomab
Sponsors: Micromet GmbH; Micromet GmbH
Recruiting - verified February 2012
Yttrium-90-labeled Daclizumab With Chemotherapy and Stem Cell Transplant for Hodgkin's Lymphoma

Conditions: Hodgkin Disease; Hodgkin Lymphoma
Interventions: Drug: Filgrastim; Drug: Plerixafor; Drug: Yttrium-Daclizumab (CHX-A Daclizumab); Drug: Carmustine; Drug: Etoposide; Drug: Cytarabine; Drug: Melphalan; Drug: Ca(2+)-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)

Condition: Type 1 Diabetes Mellitus
Intervention: Device: GBP CGM
Sponsors: University of Virginia; University of Virginia; Juvenile Diabetes Research Foundation; Becton, Dickinson and Company
Recruiting - verified November 2011
An A/B Dose Escalation Study of AbGn-7 Alone and With FOLFOX7 Treatment in Patients With Advanced Solid Tumors

Conditions: Solid Tumor of Epithelial Origin; Gastric Cancer
Interventions: Drug: AbGn-7; Drug: AbGn-7
Sponsors: AbGenomics B.V Taiwan Branch; AbGenomics B.V Taiwan Branch
Recruiting - verified December 2011
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies

Conditions: Acute Lymphoid Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Multiple Myeloma; Solid Tumors
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012
Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency

Condition: Primary Immunodeficiency
Interventions: Biological: GAMUNEX®-C; Biological: GAMUNEX®-C
Sponsors: Grifols Therapeutics Inc.; Grifols Therapeutics Inc.
Recruiting - verified April 2012
Ipilimumab and Gemcitabine Hydrochloride in Treating Patients With Stage III-IV or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery

Conditions: Acinar Cell Adenocarcinoma of the Pancreas; Duct Cell Adenocarcinoma of the Pancreas; Recurrent Pancreatic Cancer; Stage III Pancreatic Cancer; Stage IV Pancreatic Cancer
Interventions: Biological: ipilimumab; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Not yet recruiting - verified November 2011
Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage IV Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Drug: doxorubicin hydrochloride; Drug: vinblastine; Drug: dacarbazine; Procedure: quality-of-life assessment; Genetic: DNA analysis; Genetic: RNA analysis; Radiation: fludeoxyglucose F 18; Procedure: positron emission tomography; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: polymorphism analysis
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified November 2011
Study to Identify the Genetic Variations Associated With Phantom Limb Pain

Condition: Phantom Limb
Intervention: Procedure: Blood Draw
Sponsors: Henry M. Jackson Foundation for the Advancement of Military Medicine; Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences
Recruiting - verified May 2012
A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Condition: Myelodysplastic Syndrome
Interventions: Drug: Siltuximab + BSC; Drug: Placebo + BSC
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis

Condition: Multiple Sclerosis
Interventions: Drug: Ofatumumab 3mg; Drug: Ofatumumab 30mg; Drug: Ofatumumab 60mg; Drug: Placebo
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Study of ABT-700 in Subjects With Advanced Solid Tumors

Condition: Subjects With Advanced Solid Tumors (Including, But Not Limited to Gastric, Head and Neck, NSCLC, Colon, Mesothelioma and Triple Negative Breast Cancer).
Interventions: Drug: ABT-700; Drug: ABT-700 plus erlotinib; Drug: ABT-700 plus Oxaliplatin and Capecitabine
Sponsors: Abbott; Abbott
Recruiting - verified March 2012
Phase I Study of Ipilimumab (Anti-CTLA-4) in Children and Adolescents With Treatment-Resistant Cancer

Conditions: Sarcoma; Wilm's Tumor; Lymphoma; Neuroblastoma
Intervention: Drug: Ipilimumab(anti-CTLA-4 antibody)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors

Conditions: Solid Tumour; Adenocarcinoma of the Colon; Adenocarcinoma of the Pancreas
Intervention: Drug: CEP-37250/KHK2804
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.; Cephalon
Recruiting - verified February 2012
Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos

Conditions: HIV; AIDS
Intervention: Behavioral: Video or In-Person Presentation
Sponsors: Rhode Island Hospital; Rhode Island Hospital
Recruiting - verified August 2011
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Condition: Diffuse Large B-Cell Lymphoma (DLBCL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: ICE; Drug: DHAP; Procedure: Autologous Stem Cell Transplant (ASCT)
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
SS1(dsFV)PE38 Plus Pemetrexed and Cisplatin to Treat Malignant Pleural Mesothelioma

Condition: Mesothelioma
Interventions: Drug: SS1P; Drug: Pemetrexed; Drug: Cisplatin
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer

Condition: Breast Cancer
Interventions: Radiation: 111 Indium CHX-A DTPA-Trastuzumab; Drug: 111Indium Trastuzumab
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Condition: Chronic Lymphocytic Leukemia (CLL)
Interventions: Drug: MEDI-551; Drug: Rituximab; Drug: Bendamustine
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified April 2012
Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing

Conditions: Human Immunodeficiency Virus Infection; Hepatitis C
Intervention:
Sponsors: G & W Laboratories Inc.; G & W Laboratories Inc.; Alquest; SMART Biotech Ltd
Recruiting - verified October 2011
Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Biological: Elotuzumab (BMS-901608; HuLuc63)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Abbott Biotherapeutics Corp.
Recruiting - verified February 2012
Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)

Conditions: HIV Infection; Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified October 2011
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease

Condition: Crohn's Disease
Intervention: Drug: Remicade
Sponsors: Mount Sinai School of Medicine; Shradha Agarwal; Prometheus Laboratories
Recruiting - verified December 2011
SAR3419 in Acute Lymphoblastic Leukemia

Condition: Acute Lymphocytic Leukaemia
Intervention: Drug: SAR3419
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified April 2012
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant

Condition: Mantle Cell Lymphoma
Interventions: Biological: Ofatumumab; Other: Ofatumumab + Bendamustine
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; GlaxoSmithKline
Recruiting - verified January 2012
Open Label Study of Long Term Evaluation Against LDL-C Trial (OSLER)

Condition: Hypercholesterolemia
Interventions: Drug: AMG 145 and standard of care; Other: Standard of care
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma

Conditions: Melanoma; Malignant Melanoma
Intervention: Drug: CT-011
Sponsors: CureTech Ltd; CureTech Ltd
Recruiting - verified January 2012
Implementation of Nucleic Acid Amplification Testing Screening to Identify Acute and Early HIV Infection

Condition: Acute HIV Infection
Intervention: Other: Nucleic Acid Amplification Testing
Sponsors: University of California, San Diego; University of California, San Diego; National Institutes of Health (NIH)
Recruiting - verified September 2011
Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.

Condition: Oncology
Intervention: Drug: BAY94-9343
Sponsors: Bayer; Bayer
Recruiting - verified May 2012
Long-Term Safety and Tolerability of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Condition: Acute Gouty Arthritis
Intervention: Drug: Canakinumab 150mg in prefilled syringe
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
A Study of AMG 820 in Subjects With Advanced Solid Tumors

Conditions: Advanced Malignancy; Advanced Solid Tumors; Cancer; Oncology; Oncology Patients; Tumors
Intervention: Drug: AMG 820
Sponsors: Amgen; Amgen
Not yet recruiting - verified September 2011
Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease

Condition: Paget's Disease of the Vulva
Intervention: Drug: trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified August 2011
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors

Condition: Neuroblastoma
Intervention: Biological: Humanized 3F8 Monoclonal Antibody (Hu3F8)
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified March 2012
Id-KLH Vaccine + T Cells

Condition: Multiple Myeloma
Intervention: Biological: CD3/CD28
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified May 2012
A Study of Brentuximab Vedotin in Patients With CD30-positive Non-Hodgkin Lymphoma

Conditions: Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell
Intervention: Drug: brentuximab vedotin
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.
Recruiting - verified April 2012
HCV/HIV Coinfection: Antiviral Therapy and Fibrosis

Conditions: HIV Infection; Hepatitis C
Intervention:
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncutaneous Extranodal Lymphoma; Peripheral T-cell Lymphoma; Prolymphocytic Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: lenalidomide; Biological: rituximab; Other: pharmacological study; Genetic: polymorphism analysis; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
An Open-label Extension Study With Canakinumab on the Treatment and Prevention of Gout Flares up to 3 Years

Condition: Chronic Gouty Arthritis
Intervention: Biological: canakinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Tacrolimus and ATG as GVHD Prophylaxis in Patients Undergoing Related Donor HSCT

Conditions: Accelerated Phase Chronic Myelogenous Leukemia; Adult Acute Lymphoblastic Leukemia; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Peripheral T-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Previously Treated Myelodysplastic Syndromes; Primary Myelofibrosis; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Hairy Cell Leukemia; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Hodgkin Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Multiple Myeloma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Hodgkin Lymphoma; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Multiple Myeloma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Hodgkin Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Chronic Lymphocytic Leukemia; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Multiple Myeloma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Hodgkin Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Drug: tacrolimus; Biological: anti-thymocyte globulin; Other: laboratory biomarker analysis; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute
Recruiting - verified April 2012
High-Dose Cyclophosphamide and Anti-Thymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Systemic Scleroderma

Condition: Systemic Scleroderma
Interventions: Procedure: peripheral blood stem cell transplantation; Drug: cyclophosphamide; Biological: anti-thymocyte globulin; Other: questionnaire administration; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Biological: filgrastim; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
A Biomarker Study of Secukinumab in Rheumatoid Arthritis Patients

Condition: Rheumatoid Arthritis
Interventions: Biological: Placebo to Secukinumab (AIN457); Biological: Secukinumab
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
Sponsors: Progenics Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011
Extended Study of Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Condition: Prostate Cancer
Intervention: Drug: PSMA ADC
Sponsors: Progenics Pharmaceuticals, Inc.; Progenics Pharmaceuticals, Inc.
Recruiting - verified August 2011
Amatuximab for High Mesothelin Cancers

Conditions: Carcinoma, Pancreatic Ductal; Mesothelioma; Ovarian Neoplasms; Carcinoma, Non-Small-Cell Lung
Intervention: Drug: Amatuximab (MORab-009)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Radioimmunoimaging of AL Amyloidosis

Condition: AL Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
Sponsors: FDA Office of Orphan Products Development; FDA Office of Orphan Products Development; Food and Drug Administration (FDA)
Recruiting - verified August 2011
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Conditions: Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Radiation: yttrium Y 90 ibritumomab tiuxetan; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Biological: rituximab
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Association Between Hepatitis C Infection and Renal Cell Carcinoma

Conditions: Hepatitis C; Renal Cell Carcinoma; Colorectal Cancer
Intervention: Other: Hepatitis C testing
Sponsors: Henry Ford Health System; Henry Ford Health System; Schering-Plough
Recruiting - verified June 2011
Safety & Efficacy of Eculizumab to Prevent AMR in Living Donor Kidney Transplant Recipients Requiring Desensitization

Condition: Antibody Mediated Rejection
Intervention: Drug: Eculizumab
Sponsors: Alexion Pharmaceuticals; Alexion Pharmaceuticals
Recruiting - verified April 2012
A Phase 2b, Randomized, Double-blind Study to Evaluate the Efficacy of Tralokinumab in Adults With Asthma

Condition: Asthma
Intervention: Drug: Tralokinumab
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified January 2012
Fresolimumab and Radiotherapy in Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: fresolimumab (GC1008); Drug: fresolimumab (GC1008); Radiation: Radiation Therapy
Sponsors: New York University School of Medicine; New York University School of Medicine; University of California, Los Angeles
Recruiting - verified May 2012
Brentuximab Vedotin Before Autologous Stem Cell Transplant in Treating Patients With Hodgkin Lymphoma

Condition: Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: brentuximab vedotin; Other: laboratory biomarker analysis; Genetic: protein expression analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified December 2011
Sym004 in SCCHN Patients Failing Anti-EGFR Based Therapy

Condition: Carcinoma, Squamous Cell of Head and Neck
Intervention: Biological: Sym004
Sponsors: Symphogen A/S; Symphogen A/S
Recruiting - verified February 2012
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level

Conditions: Lymphoma, Non-Hodgkin; Cutaneous Lymphoma
Intervention: Drug: Brentuximab vedotin
Sponsors: Stanford University; Stanford University
Recruiting - verified December 2011
Ofatumumab and Bortezomib in Subjects With Relapsed CD20+ NHL

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Biological: ofatumumab; Drug: bortezomib; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Procedure: biopsy; Procedure: quality-of-life assessment; Genetic: polymorphism analysis; Other: flow cytometry
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI); Millennium Pharmaceuticals, Inc.; GlaxoSmithKline
Recruiting - verified April 2012
Trial of Low-Dose MTX and I 131 Tositumomab for Previously Untreated, Advanced-Stage, Follicular Lymphoma

Condition: Follicular Lymphoma
Intervention: Drug: Low dose methotrexate and Bexxar
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center; GlaxoSmithKline
Recruiting - verified August 2011
Hypofractionated Stereotactic Radiotherapy With Bevacizumab in the Treatment of Recurrent Malignant Glioma

Conditions: Brain Cancer; MALIGNANT GLIOMA; Glioblastoma; Anaplastic Astrocytoma (AA); Anaplastic Oligodendroglioma (AO); Anaplastic Oligo-astrocytoma (AOA); Anaplastic Mixed Gliomas; Malignant Glioma NOS
Intervention: Other: Bevacizumab & stereotactic radiotherapy
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Genentech; Columbia University; University of California, San Francisco
Recruiting - verified April 2012
A Study of Efficacy and Safety of Ustekinumab in Patients With Primary Biliary Cirrhosis (PBC) Who Had an Inadequate Response to Ursodeoxycholic Acid

Condition: Primary Biliary Cirrhosis
Interventions: Drug: ustekinumab (double-blind); Drug: ustekinumab (double-blind); Drug: ustekinumab (open-label); Drug: ustekinumab (double-blind); Drug: Placebo
Sponsors: Centocor Research & Development, Inc.; Centocor Research & Development, Inc.
Recruiting - verified May 2012
Study of Tocilizumab to Treat Polymyalgia Rheumatica

Condition: Polymyalgia Rheumatica (PMR)
Intervention: Drug: Tocilizumab
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; Genentech
Recruiting - verified January 2012
Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

Conditions: Light Chain Deposition Disease (LCDD or MIDD); Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD); Monoclonal Immunoglobulin Deposition Disease (MIDD); Amyloidosis
Intervention: Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Millennium Pharmaceuticals, Inc.
Recruiting - verified May 2012
Safety Study of MGA271 in Refractory Cancer

Conditions: Prostate Cancer; Pancreatic Cancer; Melanoma; Renal Cell Carcinoma; Ovarian Cancer; Colorectal Cancer; Gastric Cancer; Bladder Cancer; Non-small Cell Lung Cancer; Glioblastoma
Intervention: Biological: MGA271
Sponsors: MacroGenics; MacroGenics
Recruiting - verified December 2011
Safety Study of ²¹²Pb-TCMC-Trastuzumab Radio Immunotherapy

Conditions: Breast Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Stomach Neoplasms
Interventions: Other: ²¹²Pb-TCMC-Trastuzumab; Biological: trastuzumab
Sponsors: Areva Med LLC; Areva Med LLC
Recruiting - verified January 2012
Prospective Donor Specific Antibody (DSA) Monitoring Protocol

Conditions: Kidney Transplant; Kidney/Pancreas Transplant
Intervention:
Sponsors: Providence Health & Services; Providence Health & Services; Washington State University; Paul I Terasaki Foundation Laboratory
Recruiting - verified August 2011
Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma

Conditions: Recurrent Ovarian Cancer; Fallopian Tube Carcinoma; Primary Peritoneal Carcinoma
Intervention: Biological: Chimeric monoclonal antibody (TRC105) to CD105
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)

Conditions: Congenital Cytomegalovirus Infection; Maternal Cytomegalovirus Infection
Intervention: Drug: CMV hyperimmune globulin
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Not yet recruiting - verified June 2011
HIV Screening Take-up: Evaluating Incentives and Opt-out Strategies

Condition: HIV
Interventions: Behavioral: Monetary Incentive; Behavioral: Questionnaire Timing; Behavioral: HIV Test Offering
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institutes of Health (NIH); National Institute on Aging (NIA)
Recruiting - verified February 2012
Rheumatoid Arthritis Treatment and Biopsy Study Assessing Certolizumab Pegol (Cimzia)

Condition: Rheumatoid Arthritis
Interventions: Drug: Open Label Drug Certolizumab Pegol (CZP); Procedure: Arthroscopic synovial tissue biopsy
Sponsors: Arthritis Treatment Center, Maryland; Nathan Wei, MD, FACP, FACR:; University of California, San Diego
Recruiting - verified September 2011
TRC105 for Liver Cancer That Has Not Responded to Sorafenib

Conditions: Hepatocellular Carcinoma; Hepatocellular Cancer; Carcinoma, Hepatocellular
Intervention: Drug: TRC105
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Preventive Approach to Congenital Heart Block With Hydroxychloroquine

Conditions: Congenital Heart Block; Neonatal Lupus; Autoantibody-Associated Heart Block
Intervention: Drug: Hydroxychloroquine
Sponsors: New York University School of Medicine; New York University School of Medicine
Recruiting - verified June 2011
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis

Condition: Psoriasis
Intervention: Drug: RA-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified April 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease (UNITI-2)

Conditions: Crohn's Disease; Inflammatory Bowel Disease; IBD; Colitis
Interventions: Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo; Drug: Group 2 ustekinumab 130 mg
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified May 2012
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

Conditions: Crohn's Disease; IBD; Colitis; Inflammatory Bowel Disease
Interventions: Drug: Group 2 ustekinumab 130 mg; Drug: Group 3: ustekinumab approximately 6 mg/kg; Drug: Group 1: Placebo
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting - verified April 2012
Granulocyte Macrophage-Colony Stimulating Factor and Ipilimumab as Therapy in Melanoma

Condition: Malignant Melanoma, Metastatic
Interventions: Biological: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF); Biological: Ipilimumab
Sponsors: Northern California Melanoma Center; Lynn E. Spitler, MD; University of California, San Francisco
Recruiting - verified May 2012
Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

Condition: Leukemia
Interventions: Drug: Cyclophosphamide; Drug: Mesna; Drug: Doxorubicin; Drug: Vincristine; Drug: Dexamethasone; Drug: Ofatumumab; Drug: Methotrexate; Drug: Cytarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified May 2012
Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Conditions: Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab; Biological: ofatumumab; Procedure: biopsy
Sponsors: Northwestern University; Northwestern University; GlaxoSmithKline; National Comprehensive Cancer Network
Recruiting - verified August 2011
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

Condition: Endometrial Cancer
Interventions: Drug: Carboplatin/Paclitaxel; Drug: Trastuzumab
Sponsors: Yale University; Yale University; Genentech
Recruiting - verified January 2012
PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: R-CHOP regimen; Other: laboratory biomarker analysis; Radiation: fludeoxyglucose F 18; Radiation: selective external radiation therapy; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: National Cancer Institute (NCI); Southwest Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Phase I Biomarker Study (BMS-936558)

Condition: Renal Cell Carcinoma
Interventions: Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1); Drug: BMS-936558 (Anti-PD-1)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb; Ono Pharma
Recruiting - verified February 2012
Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients

Condition: Acute Gouty Arthritis
Interventions: Drug: Canakinumab pre-filled syringe; Drug: Canakinumab lyophilized cake; Drug: Triamcinolone Acetonide
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

Conditions: Disorder of Transplanted Kidney; Donor Specific Alloantibodies
Interventions: Drug: Bortezomib; Other: Standard posttransplant treatment
Sponsors: Mayo Clinic; Mayo Clinic; Millennium Pharmaceuticals, Inc.
Recruiting - verified December 2011
A Phase II Study Of Imtox-25 In Adults With Refractory/Relapsed Cd25 Positive Adult T Cell Leukemia/Lymphoma

Conditions: Adult T Cell Leukemia; Adult T Cell Lymphoma
Interventions: Drug: IMTOX-25; Other: IMTOX-25
Sponsors: Albert Einstein College of Medicine of Yeshiva University; Albert Einstein College of Medicine of Yeshiva University
Recruiting - verified June 2011
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)

Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma; Lymphoma, Primary Cutaneous Anaplastic Large Cell; Lymphomatoid Papulosis; Mycosis Fungoides; Skin Lymphoma; Cutaneous Lymphomas; Lymphoma; Hematologic Disorder
Intervention: Drug: SGN-35
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Seattle Genetics, Inc.
Recruiting - verified March 2012
Dose Ranging Pharmacokinetics and Pharmacodynamics Study With Mepolizumab in Asthma Patients With Elevated Eosinophils

Condition: Asthma
Interventions: Biological: Mepolizumab 250 mg subcutaneous (SC); Biological: Mepolizumab 125 mg subcutaneous (SC); Biological: Mepolizumab 12.5 mg subcutaneous (SC)
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified October 2011
A Study of IMC-CS4 in Subjects With Advanced Solid Tumors

Condition: Neoplasms
Intervention: Biological: IMC-CS4
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified October 2011
Safety and Efficacy of Intravenous Immune Globulin in Treating Spinocerebellar Ataxia

Condition: Spinocerebellar Ataxia Type 3
Intervention: Biological: IVIG
Sponsors: University of South Florida; University of South Florida; Baxter Healthcare Corporation
Recruiting - verified March 2012
Biological Therapy, Sargramostim, and Isotretinoin in Treating Patients With Relapsed or Refractory Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: hu14.18-IL2 fusion protein; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Conditions: Multiple Myeloma; Renal Insufficiency
Interventions: Drug: BHQ880; Drug: BHQ990
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Study of Cabazitaxel Plus Bavituximab as Second-line Chemotherapy for Patients With Castration-resistant Prostate Cancer

Conditions: Prostate Cancer; Prostatic Neoplasms
Intervention: Drug: Cabazitaxel plus bavituximab
Sponsors: University of California, Irvine; University of California, Irvine; Peregrine Pharmaceuticals
Recruiting - verified August 2011
Study of TRC105 Combined With Standard-Dose Bevacizumab for Advanced Solid Tumors for Which Bevacizumab is Indicated

Condition: Adult Solid Tumor
Intervention: Drug: TRC105 and Bevacizumab
Sponsors: Tracon Pharmaceuticals Inc.; Tracon Pharmaceuticals Inc.
Recruiting - verified March 2012
Trial of Induction Chemotherapy (ICT) Followed by Concurrent Chemoraditherapy (CR) With Monoclonal Antibody Cetuximab in Locally Advanced Head and Neck Squamous Cell Cancer

Condition: Head and Neck Squamous Cell Cancer
Intervention: Drug: Cetuximab
Sponsors: Louisiana State University Health Sciences Center Shreveport; Louisiana State University Health Sciences Center Shreveport
Recruiting - verified April 2012
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)

Condition: Atherosclerosis
Interventions: Drug: Canakinumab; Drug: Placebo
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage III Salivary Gland Cancer; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Squamous Cell Carcinoma of the Nasopharynx; Stage III Squamous Cell Carcinoma of the Oropharynx; Stage III Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Drug: TLR8 agonist VTX-2337; Biological: cetuximab; Other: laboratory biomarker analysis; Other: pharmacogenomic studies; Other: flow cytometry; Other: immunoenzyme technique
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer

Conditions: Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IVA Colon Cancer; Stage IVA Rectal Cancer; Stage IVB Colon Cancer; Stage IVB Rectal Cancer
Interventions: Drug: oxaliplatin; Drug: leucovorin calcium; Drug: fluorouracil; Biological: bevacizumab; Procedure: therapeutic conventional surgery; Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A; Other: laboratory biomarker analysis; Other: pharmacological study; Drug: irinotecan hydrochloride
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen

Conditions: Hematologic Malignancies; Disorder Related to Transplantation; Hematopoietic Malignancy
Intervention: Genetic: Preparative Regimen
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified December 2011
Behavioral Science Aspects of Rapid Test Acceptance

Conditions: HIV; Hepatitis C; Hepatitis B; Syphilis
Interventions: Device: Rapid tests for HIV, HCV, HBV, and syphilis; Device: HIV/HCV; Device: HIV/syphilis; Device: HIV only
Sponsors: California State University, Long Beach; California State University, Long Beach; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012
Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma

Conditions: Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma
Interventions: Procedure: peripheral blood stem cell transplantation (PBSCT); Biological: filgrastim; Genetic: polymerase chain reaction; Biological: rituximab; Biological: genetically engineered lymphocyte therapy; Other: laboratory biomarker analysis; Drug: plerixafor; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer

Conditions: Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma; Recurrent Metastatic Squamous Neck Cancer With Occult Primary; Recurrent Salivary Gland Cancer; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Squamous Cell Carcinoma of the Nasopharynx; Recurrent Squamous Cell Carcinoma of the Oropharynx; Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Salivary Gland Squamous Cell Carcinoma; Stage IV Salivary Gland Cancer; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IV Squamous Cell Carcinoma of the Larynx; Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IV Squamous Cell Carcinoma of the Nasopharynx; Stage IV Squamous Cell Carcinoma of the Oropharynx; Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity; Stage IV Verrucous Carcinoma of the Larynx; Stage IV Verrucous Carcinoma of the Oral Cavity; Tongue Cancer; Untreated Metastatic Squamous Neck Cancer With Occult Primary
Interventions: Biological: cetuximab; Drug: paclitaxel; Drug: carboplatin; Drug: erlotinib hydrochloride; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Procedure: biopsy
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified September 2011
A Study of IMC-3G3 in Previously Treated Patients With Unresectable and/or Metastatic Gastrointestinal Stromal Tumors

Condition: Gastrointestinal Stromal Tumor (GIST)
Intervention: Biological: IMC-3G3
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified March 2012
A 3-arm Proof of Concept Study of AIN457, ACZ885 or Corticosteroids in Patients With Polymyalgia Rheumatica

Conditions: Polymyalgia Rheumatica; Inflammatory Diseases
Interventions: Drug: AIN457; Drug: ACZ885 (canakinumab); Drug: Prednisone
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease

Conditions: Sclerodermoid Chronic Graft-versus-host Disease; Graft Versus Host Disease in Skin
Interventions: Drug: imatinib mesylate; Biological: rituximab; Other: questionnaire; Other: blood samples; Other: skin biopsies
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Panitumumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Advanced Esophageal or Gastroesophageal Junction Cancer

Conditions: Adenocarcinoma of the Esophagus; Adenocarcinoma of the Gastroesophageal Junction; Stage II Esophageal Cancer
Interventions: Biological: panitumumab; Drug: oxaliplatin; Drug: leucovorin calcium; Drug: fluorouracil; Radiation: radiation therapy; Procedure: therapeutic conventional surgery; Other: laboratory biomarker analysis; Other: high performance liquid chromatography; Genetic: DNA analysis; Genetic: polymorphism analysis; Other: pharmacological study; Other: pharmacogenomic studies
Sponsors: University of Nebraska; University of Nebraska; National Cancer Institute (NCI)
Recruiting - verified July 2011
Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type KRAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: panitumumab; Drug: Randomization to No Panitumumab
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; Amgen
Recruiting - verified March 2012
Bavituximab Plus Carbo and Pemetrexed in Chemo-Naive Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Subjects

Condition: Non Small Cell Lung Cancer (NSCLC)
Intervention: Drug: Bavituximab
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; Peregrine Pharmaceuticals
Recruiting - verified April 2012
Sorafenib and TRC105 in Hepatocellular Cancer

Conditions: Hepatoma; Liver Neoplasms; Adenoma, Liver Cell; Carcinoma, Hepatocellular
Interventions: Drug: TRC 105; Drug: Sorafenib
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified December 2011
Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Secondary Acute Myeloid Leukemia
Interventions: Radiation: Indium-111 111In anti-CD45 monoclonal antibody BC8 (dosimetric dose); yttrium Y 90 anti-CD45 monoclonal antibody BC8 (therapeutic dose); Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Other: flow cytometry; Genetic: cytogenetic analysis; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Induction and Maintenance Study of BMS-936557 Patients With Moderate to Severe Ulcerative Colitis

Condition: Colitis, Ulcerative
Interventions: Drug: Placebo; Drug: Placebo; Drug: Anti-IP-10 Antibody; Drug: Anti-IP-10 Antibody; Drug: Anti-IP-10 Antibody; Drug: Anti-IP-10 Antibody; Drug: Anti-IP-10 Antibody; Drug: Anti-IP-10 Antibody
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified March 2012
Carboplatin and Bevacizumab for Recurrent Ependymoma

Conditions: Brain Tumor; Spinal Tumor; Glial Tumour of Brain; Ependymal Tumour of Brain; Spinal Cord Ependymoma; Anaplastic Ependymoma
Interventions: Drug: Bevacizumab; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified February 2012
Study of US-ATG-F to Prevent Chronic Graft Versus Host Disease (GVHD)

Conditions: GVHD; Adult Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndrome
Interventions: Biological: Anti-human-T-lymphocyte Immune Globulin, Rabbit; Biological: Placebo
Sponsors: Fresenius Biotech GmbH; Fresenius Biotech GmbH; Fresenius Biotech North America
Recruiting - verified April 2012
Panitumumab and Gemcitabine in Relapsed Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
Intervention: Biological: Panitumumab
Sponsors: Women and Infants Hospital of Rhode Island; Women and Infants Hospital of Rhode Island; Amgen
Recruiting - verified March 2012
A Study of Anti-VEGFR-3 Monoclonal Antibody IMC-3C5 in Subjects With Advanced Solid Tumors

Condition: Neoplasms
Intervention: Biological: IMC-3C5
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency

Conditions: Primary Immune Deficiency Disorders; Common Variable Immunodeficiency; X-linked Agammaglobulinemia; Hyper-IgM Syndrome; Wiskott-Aldrich Syndrome
Intervention: Biological: Gammaplex
Sponsors: Bio Products Laboratory; Bio Products Laboratory
Recruiting - verified February 2012
Intravenous Immunoglobulin for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections)

Conditions: Obsessive-Complusive Disorder; Children; Anxiety Disorder; Autoimmune Disease; PANDAS
Interventions: Drug: Gamunex Intravenous Immunoglobulin; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified October 2011
AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer

Conditions: Colonic Neoplasms; Cancer of the Colon; Colon Cancer; Colon Neoplasms; Colonic Cancer
Interventions: Drug: Cetuximab; Drug: AZD6244
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified October 2011
Combination Chemotherapy and Cetuximab or Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin; Drug: irinotecan hydrochloride; Biological: bevacizumab; Biological: cetuximab; Drug: capecitabine; Genetic: mutation analysis; Genetic: gene expression analysis; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: nucleic acid sequencing; Genetic: protein expression analysis; Genetic: polymerase chain reaction; Genetic: DNA analysis
Sponsors: Fox Chase Cancer Center; Fox Chase Cancer Center; National Cancer Institute (NCI)
Recruiting - verified October 2011
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds

Conditions: HIV Infection; Hepatitis C
Interventions: Drug: Anti-HIV Agents; Drug: raltegravir; Drug: Emtricitabine and tenofovir disoproxil fumarate
Sponsors: Johns Hopkins University; Johns Hopkins University; National Institute on Drug Abuse (NIDA)
Recruiting - verified August 2011
Study of BHQ880 in Patients With High Risk Smoldering Multiple Myeloma

Condition: Smoldering Multiple Myeloma
Intervention: Drug: BHQ880
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified May 2012
Study of Anti-HB-EGF Antibody KHK2866 in Subjects With Advanced Solid Tumors and Ovarian Cancer

Conditions: Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Primary Peritoneal Neoplasm
Interventions: Biological: KHK2866; Drug: Gemcitabine and Carboplatin; Drug: paclitaxel; Drug: pegylated liposomal doxorubicin
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified February 2012
Study of TF2 Carcinoembryonic Antigen (CEA) Antibody in Patients With Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: TF2/IMP288
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.; National Cancer Institute (NCI)
Not yet recruiting - verified March 2012
Environmental Risk Factors for the Anti-synthetase Syndrome

Condition: Myositis
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Environmental Health Sciences (NIEHS)
Recruiting - verified August 2011
Study of HCD122 (Lucatumumab) and Bendamustine Combination Therapy in CD40+ Relapsed Follicular Lymphoma

Condition: Follicular Lymphoma
Intervention: Drug: HCD122
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified March 2012
Safety and Preliminary Efficacy Study of an Anti-inflammatory Therapeutic Antibody in Reducing Restenosis.

Condition: Patients Undergoing Repeat Peripheral Artery Revascularization
Intervention: Drug: CV-18C3
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified May 2012
A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Conditions: Mesothelioma; Pancreatic Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Drug: Amatuximab
Sponsors: Morphotek; Morphotek
Recruiting - verified January 2012
Trial of Gemcitabine With or Without Bavituximab in Patients With Previously Untreated Stage IV Pancreatic Cancer

Condition: Metastatic Pancreatic Cancer
Interventions: Biological: bavituximab; Drug: Gemcitabine
Sponsors: Peregrine Pharmaceuticals; Peregrine Pharmaceuticals
Recruiting - verified May 2012
Study of IMMU-130 in Patients With Relapsed/Refractory Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Intervention: Drug: IMMU-130
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified April 2012
Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

Conditions: Contiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Mantle Cell Lymphoma; Stage I Mantle Cell Lymphoma; Stage III Mantle Cell Lymphoma; Stage IV Mantle Cell Lymphoma
Interventions: Drug: bortezomib; Biological: rituximab; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: RNA analysis; Genetic: gene expression analysis; Genetic: DNA analysis; Other: pharmacological study; Other: pharmacogenomic studies
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

Conditions: B-cell Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Stage 0 Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab; Drug: PGG beta-glucan; Other: flow cytometry; Other: laboratory biomarker analysis; Genetic: DNA analysis; Genetic: fluorescence in situ hybridization; Genetic: polymerase chain reaction; Genetic: polymorphism analysis; Genetic: mutation analysis
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified April 2012
Bevacizumab Versus Bevacizumab Plus Vorinostat in Adults With Recurrent Glioblastoma

Condition: Brain Cancer
Interventions: Drug: Vorinostat; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Vorinostat
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified April 2012
BATTLE-FL: Front-Line Biomarker-Integrated Treatment Study in Non Small Cell Lung Cancer

Condition: Lung Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Bevacizumab; Drug: Cetuximab; Drug: Cixutumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Eli Lilly and Company; Genentech; ImClone LLC
Recruiting - verified May 2012
Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Interventions: Drug: Standard of care treatment; Drug: eculizumab
Sponsors: University of North Carolina, Chapel Hill; University of North Carolina, Chapel Hill; Alexion Pharmaceuticals; National Institutes of Health (NIH); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified December 2011
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Epratuzumab; Drug: Epratuzumab; Drug: Placebo
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Placebo; Drug: Epratuzumab; Drug: Epratuzumab
Sponsors: UCB, Inc.; UCB, Inc.
Recruiting - verified May 2012
A Study to Evaluate the Safety, Tolerability, and Activity of Intravenous MLDL1278A in Patients on Standard-of-Care Therapy for Stable Atherosclerotic Cardiovascular Disease (GLACIER)

Condition: Atherosclerosis
Interventions: Drug: MLDL1278A; Drug: MLDL1278A; Drug: placebo; Drug: statin, stable dose
Sponsors: Genentech; Genentech; BioInvent International AB
Recruiting - verified February 2012
Brivanib Metastatic Renal Cell Carcinoma

Condition: Male and Female Subjects 18 Years of Age and Older With Metastatic Renal Cell Carcinoma. Eligible Patients Must Have Undergone and Failed Prior Treatment.
Interventions: Drug: Brivanib alaninate; Genetic: Polymerase chain reaction; Other: Iodine I 124 chimeric monoclonal antibody G250; Procedure: Positron emission tomography/computed tomography; Genetic: Protein expression analysis; Other: Immunohistochemistry
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012
Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

Conditions: Colorectal Cancer; Head and Neck Cancer
Interventions: Biological: cetuximab; Drug: lenalidomide; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Arthur G. James Cancer Hospital & Richard J. Solove Research Institute; National Cancer Institute (NCI)
Recruiting - verified June 2011
A Randomized Controlled Trial of the Bruthas Project

Condition: HIV Infection
Interventions: Behavioral: Bruthas Project; Behavioral: Standard HIV Testing and Counseling
Sponsors: University of California, San Francisco; University of California, San Francisco; National Institute of Mental Health (NIMH)
Recruiting - verified January 2012
Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer

Conditions: Hepatocellular Carcinoma; Liver Cancer
Intervention: Drug: bavituximab and sorafenib
Sponsors: University of Texas Southwestern Medical Center; University of Texas Southwestern Medical Center
Recruiting - verified October 2010
A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma

Conditions: Myeloma; Smoldering Multiple Myeloma
Intervention: Drug: IHP2101 (anti-KIR)
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001 AM2)

Condition: Clostridium Difficile Infection
Interventions: Biological: MK-3415; Biological: MK-6072; Biological: MK-3415A; Biological: Placebo
Sponsors: Merck; Merck
Recruiting - verified May 2012
A Study of RO4905417 in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery

Condition: Coronary Heart Disease, Graft Occlusion, Vascular
Interventions: Drug: RO4905417; Drug: Placebo
Sponsors: Hoffmann-La Roche; Hoffmann-La Roche
Recruiting - verified April 2012
A Study of the Safety and Efficacy of CNTO 148 (Golimumab) in Children With Juvenile Idiopathic Arthritis (JIA) and Multiple Joint Involvement Who Have Poor Response to Methotrexate (GO KIDS)

Condition: Juvenile Idiopathic Arthritis
Interventions: Biological: CNTO 148 (Golimumab); Biological: CNTO 148 (golimumab) or placebo
Sponsors: Centocor, Inc.; Centocor, Inc.; Schering-Plough (Ireland) Company
Recruiting - verified May 2012
MPA-monotherapy in Liver Transplant

Condition: Liver Transplant
Interventions: Drug: Withdrawal of Tacrolimus to mycophenolate monotherapy; Other: data and sample collection; Other: data and sample collection
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Novartis Pharmaceuticals
Recruiting - verified November 2011
Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001

Conditions: Peripheral T-cell Lymphoma; Cutaneous T-cell Lymphoma
Intervention: Biological: KW-0761
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin Pharma, Inc.
Recruiting - verified May 2012
FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only

Condition: Colorectal Cancer
Interventions: Drug: Panitumumab; Drug: Oxaliplatin; Drug: Irinotecan; Drug: Leucovorin; Drug: 5-Fluorouracil
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen
Recruiting - verified July 2011
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy

Condition: Kidney Cancer
Interventions: Drug: Pazopanib; Drug: Bevacizumab; Drug: Everolimus
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified December 2011
Hepatic Arterial Infusion Oxaliplatin, Capecitabine With or Without Bevacizumab

Condition: Advanced Cancers
Interventions: Drug: Oxaliplatin; Drug: Capecitabine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Bendamustine and Rituximab Followed by 90-yttrium (Y) Ibritumomab Tiuxetan for Untreated Follicular Lymphoma

Condition: Lymphoma, Follicular
Interventions: Drug: Bendamustine; Drug: Rituximab; Radiation: Y-90 ibritumomab
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center; Cephalon; Spectrum Pharmaceuticals, Inc
Recruiting - verified October 2011
A Study to Assess AFM13 in Patients With Hodgkin Lymphoma

Condition: Hodgkin Lymphoma
Intervention: Drug: AFM 13
Sponsors: Affimed Therapeutics AG; Affimed Therapeutics AG
Recruiting - verified February 2011
Study of KB004 in Subjects With Hematologic Malignancies

Conditions: Acute Myeloid Leukemia (AML); Acute Lymphocytic Leukemia (ALL); Chronic Myelogenous Leukemia (CML); Myelodysplastic Syndrome (MDS); Myeloproliferative Neoplasms (MPN)
Intervention: Drug: KB004, Monoclonal Antibody
Sponsors: KaloBios Pharmaceuticals; KaloBios Pharmaceuticals
Recruiting - verified October 2011
Immunotherapy for Asymptomatic Phase Lymphoplasmacytic Lymphoma

Condition: Lymphoma
Intervention: Biological: DNA Vaccine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Not yet recruiting - verified May 2012
Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Conditions: Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer
Interventions: Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: fluorouracil; Biological: bevacizumab; Radiation: yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A; Other: laboratory biomarker analysis
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Study of Fixed Dose Radioimmunotherapy (Zevalin, Yttrium-90 Ibritumomab Tiuxetan) for Patients With Incomplete Response to Chemotherapy Prior to Autologous Stem Cell Transplant for Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: indium-111-ibritumomab tiuxetan
Sponsors: Tufts Medical Center; Tufts Medical Center; Spectrum Pharmaceuticals, Inc
Recruiting - verified April 2012
Identifying Undiagnosed Asymptomatic HIV Infection in Hispanic/Latino Adolescents and Young Adults

Condition: HIV
Intervention: Behavioral: Effectiveness of different strategies in HIV testing and linkage to care
Sponsors: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); National Institute on Drug Abuse (NIDA); National Institute of Mental Health (NIMH)
Recruiting - verified January 2011
Hormone Blockade in Combination With Targeted Agents

Conditions: Solid Tumors; Advanced Cancer
Interventions: Drug: Anastrozole; Drug: Bevacizumab; Drug: Everolimus; Drug: Sorafenib; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
CAPOX in KRAS Wild-Type Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Condition: Gastrointestinal Cancer
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Panitumumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Amgen
Recruiting - verified May 2012
A Phase I Study of MGAH22 in Patients With Refractory HER2 Positive Cancers

Conditions: Non-Small Cell Lung Neoplasms; Prostate Neoplasms; Bladder Neoplasms; Ovarian Neoplasms; Breast Neoplasms
Intervention: Drug: MGAH22
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified March 2012
Bevacizumab With Capecitabine and Oxaliplatin in Advanced Adenocarcinoma of the Small Bowel or Ampulla of Vater

Condition: Gastrointestinal Cancers
Interventions: Drug: Capecitabine; Drug: Oxaliplatin; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified March 2012
Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use NSAIDs and/or Colchicine.

Condition: Acute Gout
Intervention: Drug: ACZ885
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified April 2012
Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)

Condition: Leukemia
Intervention: Drug: Alemtuzumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Avastin/Torisel With Carboplatin, Taxol, or Sorafenib

Condition: Advanced Cancer
Interventions: Drug: Temsirolimus; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Sorafenib; Drug: Carboplatin
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of First Remission After Myeloablative Therapy and Autologous Stem-Cell Transplantation

Condition: Neuroblastoma
Intervention: Drug: 3F8 monoclonal antibody and 13-cis-Retinoic Acid
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)

Condition: Advanced Cancers
Interventions: Drug: Lenalidomide; Drug: Bevacizumab; Drug: Sorafenib; Drug: Temsirolimus; Drug: Lenalidomide; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-fluorouracil
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation
Recruiting - verified May 2012
A Study of IMC-3G3 in Soft Tissue Sarcoma

Condition: Sarcoma, Soft Tissue
Interventions: Biological: IMC-3G3; Drug: doxorubicin; Drug: dexrazoxane
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy

Condition: Liver Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech; OSI Pharmaceuticals
Recruiting - verified March 2012
Rituximab + Immune Globulin Intravenous (IVIG) for Desensitization

Condition: End Stage Renal Disease
Intervention: Biological: Rituxan
Sponsors: Cedars-Sinai Medical Center; Stanley Jordan, MD; Genentech
Recruiting - verified March 2012
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Stage IV Melanoma That Has Been Removed By Surgery

Condition: Melanoma (Skin)
Interventions: Biological: MART-1:26-35(27L) peptide vaccine; Biological: NY-ESO-1 peptide vaccine; Biological: anti-PD-1 human monoclonal antibody MDX-1106; Biological: gp100:209-217(210M) peptide vaccine; Biological: gp100:280-288(288V) peptide vaccine; Drug: Montanide ISA 51 VG; Other: laboratory biomarker analysis; Other: pharmacological study
Sponsors: National Cancer Institute (NCI); H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI)
Recruiting - verified September 2011
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Primary Refractory Neuroblastoma in Bone Marrow

Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
High-Dose 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

Condition: Neuroblastoma
Intervention: Biological: 3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified April 2012
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer

Conditions: Biliary Tract Cancer; Gallbladder Cancer
Interventions: Drug: Panitumumab; Drug: oxaliplatin; Drug: gemcitabine
Sponsors: University of Rochester; University of Rochester; Amgen
Recruiting - verified November 2011
Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Condition: Hemophilia A
Intervention: Biological: OBI-1
Sponsors: Inspiration Biopharmaceuticals, Inc.; Inspiration Biopharmaceuticals, Inc.
Recruiting - verified April 2012
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 (Human Immunodeficiency Virus-1) Infected Adults on ART

Condition: HIV-1 Infection
Intervention: Biological: JS7 plasmid DNA and MVA62B vaccine
Sponsors: GeoVax, Inc.; GeoVax, Inc.; AIDS Research Consortium of Atlanta; University of Alabama at Birmingham; AIDS Research Alliance
Recruiting - verified December 2011
Home Self-Testing for HIV to Increase HIV Testing Frequency in Men Who Have Sex With Men (The iTest Study)

Condition: HIV
Interventions: Behavioral: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test; Device: Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test
Sponsors: University of Washington; University of Washington; Public Health - Seattle and King County; National Institute of Mental Health (NIMH)
Recruiting - verified February 2012
Phase II Study of IMC-A12 in Patients With Mesothelioma Who Have Been Previously Treated With Chemotherapy

Conditions: Pleural Mesothelioma; Peritoneal Mesothelioma
Intervention: Drug: IMC-A12
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified January 2012
A Study of Pemetrexed & Carboplatin/Cisplatin or Gemcitabine & Carboplatin/Cisplatin With or Without IMC-1121B in Patients Previously Untreated With Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Biological: 1121B (ramucirumab); Drug: Pemetrexed; Drug: Carboplatin (AUC 6); Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin (AUC 5)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified December 2011
OIT and Xolair® (Omalizumab) in Cow's Milk Allergy

Condition: Milk Allergy
Interventions: Biological: Xolair® (omalizumab) placebo/milk OIT; Biological: Xolair® (omalizumab)/milk OIT
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Bendamustine and Bevacizumab for Advanced Cancers

Condition: Advanced Cancer
Interventions: Drug: Bendamustine; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Cephalon; National Comprehensive Cancer Network
Recruiting - verified March 2012
Evaluating Safety and Efficacy of TOL101 Induction Versus Anti-Thymocyte Globulin to Prevent Kidney Transplant Rejection

Conditions: End Stage Renal Disease; Renal Transplant
Interventions: Drug: Anti-Thymocyte Globulin; Drug: TOL101; Drug: TOL101; Drug: Steroids; Drug: Tacrolimus; Drug: Mycophenolate mofetil (MMF)
Sponsors: Tolera Therapeutics, Inc; Tolera Therapeutics, Inc
Recruiting - verified September 2011
Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Conditions: Giant Cell Glioblastoma; Glioblastoma; Gliosarcoma
Interventions: Biological: bevacizumab; Drug: temozolomide; Other: laboratory biomarker analysis; Other: immunohistochemistry staining method; Genetic: microarray analysis; Genetic: DNA methylation analysis
Sponsors: University of California, Los Angeles; University of California, Los Angeles; Genentech
Recruiting - verified February 2012
Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies and Select Untreated Lymphomas

Conditions: Adult Grade III Lymphomatoid Granulomatosis; Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Chronic Lymphocytic Leukemia; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage I Small Lymphocytic Lymphoma; Stage II Adult Burkitt Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Grade 1 Follicular Lymphoma; Stage II Grade 2 Follicular Lymphoma; Stage II Grade 3 Follicular Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome; Stage IV Small Lymphocytic Lymphoma; Waldenström Macroglobulinemia
Interventions: Drug: bendamustine hydrochloride; Drug: carboplatin; Biological: rituximab; Drug: etoposide
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Evaluation of InnoLIA HTLV I/II Score

Condition: Human T-cell Lymphotropic Virus
Intervention: Device: InnoLIA HTLV I/II Score line immunoassay
Sponsors: Creative Testing Solutions; Creative Testing Solutions
Not yet recruiting - verified June 2010
A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

Condition: Graft Rejection
Interventions: Biological: Placebo; Biological: C1 Esterase Inhibitor (Human)
Sponsors: ViroPharma; ViroPharma
Recruiting - verified April 2012
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients

Condition: Sensitized Post Kidney Transplant Recipients
Intervention: Procedure: bone marrow aspirations
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified December 2011
Evaluation of Meningococcal Immune Response Among Children Who Previously Received MenACWY Conjugate Vaccine

Condition: Meningococcal Meningitis
Interventions: Biological: Meningococcal ACWY conjugate vaccine; Biological: Meningococcal ACWY conjugate vaccine
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012
Safety Study of MGAH22 in HER2-positive Carcinomas

Conditions: Breast Cancer; Gastric Cancer; Bladder Cancer; Ovarian Cancer; Non-small Cell Lung Cancer
Intervention: Biological: MGAH22
Sponsors: MacroGenics; MacroGenics; Green Cross Corporation; National Cancer Institute (NCI)
Recruiting - verified April 2012
Evaluation of Panel Reactive Antibody in Children Following Stage I Palliation for Hypoplastic Left Heart Syndrome

Condition: Congenital Heart Disease
Intervention:
Sponsors: Children's Hospital of Philadelphia; Children's Hospital of Philadelphia
Recruiting - verified December 2011
A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Patients With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib

Condition: Hepatocellular Carcinoma
Interventions: Biological: Placebo; Biological: Ramucirumab DP (IMC-1121B)
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Safety & Tolerability of Berinert® (C1 Inhibitor) Therapy to Prevent Rejection

Condition: Kidney Transplantation
Intervention: Biological: C1 Esterase Inhibitor
Sponsors: Cedars-Sinai Medical Center; Stanley Jordan, MD; CSL Behring
Recruiting - verified March 2012
Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

Condition: Alzheimer's Disease
Intervention: Drug: Solanezumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Trial of Panitumumab/Cisplatin/Fluorouracil With XRT in Esophageal Cancer

Condition: Cancer
Intervention: Drug: Panitumumab
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Amgen
Recruiting - verified February 2012
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas

Conditions: Acoustic Schwannoma; Adult Anaplastic Meningioma; Adult Ependymoma; Adult Grade I Meningioma; Adult Grade II Meningioma; Adult Meningeal Hemangiopericytoma; Adult Papillary Meningioma; Neurofibromatosis Type 1; Neurofibromatosis Type 2; Recurrent Adult Brain Tumor
Intervention: Biological: bevacizumab
Sponsors: Northwestern University; Northwestern University
Recruiting - verified May 2012
Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: prednisone; Drug: adalimumab placebo
Sponsors: Abbott; Abbott
Recruiting - verified February 2012
Efficacy and Safety of Adalimumab in Subjects With Active Uveitis

Condition: Uveitis
Interventions: Drug: adalimumab; Drug: prednisone; Drug: adalimumab placebo; Drug: prednisone
Sponsors: Abbott; Abbott
Recruiting - verified February 2012
First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers

Conditions: Acute Myelogenous Leukemia; Diffuse Large B-Cell Leukemia; Chronic Lymphocytic Leukemia; Follicular Lymphoma
Interventions: Drug: BMS-936564 (Anti-CXCR4); Drug: BMS-936564 (Anti-CXCR4)
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified December 2011
A Study of IMC-RON8 in Advanced Solid Tumors

Condition: Cancer
Interventions: Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8; Biological: IMC-RON8
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified November 2011
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Nab-paclitaxel; Drug: Bevacizumab; Drug: Gemcitabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Randomized, Placebo-controlled, Double-blind Pilot Study of Single-dose Humanized Anti-IL5 Antibody (Reslizumab) for the Reduction of Eosinophilia Following Diethylcarbamazine Treatment of Loa Loa Infection

Condition: Loiasis
Interventions: Drug: Reslizumab; Drug: Diethylcarbamazine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified February 2012
Immunoglobulin, Diagnosis, Evaluation, and Key Learnings Patient Registry (IDEaL™)

Condition: IVIg or SCIg Therapy in the Home or at Alternate Site
Intervention:
Sponsors: Coram Clinical Trials; Coram Clinical Trials
Recruiting - verified July 2011
A Study in Patients With Diabetic Kidney Disease

Conditions: Diabetic Kidney Disease; Diabetic Nephropathy; Diabetic Glomerulosclerosis
Interventions: Drug: LY2382770; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified May 2012
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma

Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Biological: CD40 agonist monoclonal antibody CP-870,893; Biological: tremelimumab; Other: laboratory biomarker analysis
Sponsors: Abramson Cancer Center of the University of Pennsylvania; Abramson Cancer Center of the University of Pennsylvania
Recruiting - verified February 2012
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)

Condition: Disease, Hodgkin
Interventions: Drug: brentuximab vedotin; Drug: placebo
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer

Conditions: Colon Cancer; Rectal Cancer
Interventions: Biological: IMC-1121B; Biological: IMC-18F1; Drug: mFOLFOX-6
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified April 2012
Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Conditions: Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Primary Central Nervous System Non-Hodgkin Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: filgrastim; Drug: plerixafor; Biological: rituximab; Drug: ifosfamide; Drug: carboplatin; Drug: etoposide; Procedure: leukapheresis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Elitek (Rasburicase) Immuno-Monitoring Study

Condition: Tumor Lysis Syndrome
Intervention:
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified February 2012
Eculizumab Added to Conventional Treatment in the Prevention of Antibody-mediated Rejection in ABO Blood Group Incompatible Living Donor Kidney Transplantation

Condition: Kidney Transplant
Intervention: Drug: eculizumab
Sponsors: Mayo Clinic; Mayo Clinic; Alexion Pharmaceuticals
Recruiting - verified April 2012
MM-111 in Combination With Herceptin in Patients With Advanced Her2 Amplified, Heregulin Positive Breast Cancer

Conditions: HER2 Amplified Breast Cancer; Metastatic or Advanced Breast Cancer
Intervention: Drug: MM-111 and Herceptin
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals
Recruiting - verified March 2012
Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Erythroleukemia (M6a); Adult Nasal Type Extranodal NK/T-cell Lymphoma; Adult Pure Erythroid Leukemia (M6b); B-cell Adult Acute Lymphoblastic Leukemia; B-cell Childhood Acute Lymphoblastic Leukemia; Blastic Phase Chronic Myelogenous Leukemia; Burkitt Lymphoma; Childhood Acute Erythroleukemia (M6); Childhood Acute Lymphoblastic Leukemia in Remission; Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Minimally Differentiated Myeloid Leukemia (M0); Childhood Acute Monoblastic Leukemia (M5a); Childhood Acute Monocytic Leukemia (M5b); Childhood Acute Myeloid Leukemia in Remission; Childhood Chronic Myelogenous Leukemia; Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Childhood Myelodysplastic Syndromes; Childhood Nasal Type Extranodal NK/T-cell Lymphoma; Chronic Myelomonocytic Leukemia; Chronic Phase Chronic Myelogenous Leukemia; Cutaneous B-cell Non-Hodgkin Lymphoma; de Novo Myelodysplastic Syndromes; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Juvenile Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Nodal Marginal Zone B-cell Lymphoma; Previously Treated Myelodysplastic Syndromes; Prolymphocytic Leukemia; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Acute Lymphoblastic Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Recurrent Childhood Anaplastic Large Cell Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Relapsing Chronic Myelogenous Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes; Secondary Myelofibrosis; Splenic Marginal Zone Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia; T-cell Adult Acute Lymphoblastic Leukemia; T-cell Childhood Acute Lymphoblastic Leukemia; T-cell Large Granular Lymphocyte Leukemia; Waldenstrom Macroglobulinemia
Interventions: Procedure: double-unit umbilical cord blood transplantation; Other: cytogenetic analysis; Procedure: bone marrow aspiration; Other: fluorescence in situ hybridization; Drug: busulfan; Drug: cyclophosphamide; Drug: anti-thymocyte globulin; Drug: methylprednisolone; Drug: cyclosporine; Drug: mycophenolate mofetil; Other: flow cytometry; Procedure: allogeneic hematopoietic stem cell transplantation
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified January 2012
Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)

Condition: Rheumatoid Arthritis
Intervention: Drug: Certolizumab
Sponsors: University of Rochester; University of Rochester
Recruiting - verified October 2011
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies

Condition: Leukemia
Intervention: Drug: Nelarabine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; GlaxoSmithKline
Recruiting - verified January 2012
Radiosurgery Plus Bevacizumab in Glioblastoma

Conditions: Glioblastoma; Gliosarcoma; Brain Tumor
Interventions: Radiation: radiosurgery; Biological: bevacizumab; Drug: irinotecan hydrochloride
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center
Recruiting - verified March 2012
Irinotecan and Bevacizumab for Recurrent Ovarian Cancer

Conditions: Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Carcinoma
Intervention: Drug: Irinotecan and Bevacizumab
Sponsors: New York University School of Medicine; New York University School of Medicine; Genentech
Recruiting - verified March 2012
A Study of hLL1-DOX (Milatuzumab-Doxorubicin Antibody-Drug Conjugate) in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Drug: hLL1-DOX (the doxorubicin conjugate of milatuzumab)
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified February 2012
Dose Escalation Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies

Condition: Hematological Malignancy
Intervention: Drug: SAR650984
Sponsors: Sanofi-Aventis; Sanofi-Aventis
Recruiting - verified March 2012
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Conditions: Hairy Cell Leukemia (HCL); Chronic Lymphocytic Leukemia (CLL); Non-Hodgkins Lymphoma (NHL); Cutaneous T Cell Lymphoma (CTCL); Adult T Cell Lymphoma (ATL)
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified September 2011
Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

Condition: Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
Interventions: Biological: Rituximab; Other: Placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011
Study To Assess Fracture Healing With Sclerostin Antibody

Condition: Fracture Healing
Interventions: Drug: Placebo; Drug: AMG 785 140 mg; Drug: AMG785 70mg; Drug: AMG 785 210mg
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Irinotecan Hydrochloride and Cetuximab With or Without Ramucirumab in Treating Patients With Advanced Colorectal Cancer With Progressive Disease After Treatment With Bevacizumab-Containing Chemotherapy

Condition: Colorectal Cancer
Interventions: Biological: cetuximab; Biological: ramucirumab; Drug: irinotecan hydrochloride
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2012
A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Condition: Arthritis, Psoriatic
Interventions: Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: placebo; Drug: placebo; Drug: ustekinumab; Drug: ustekinumab; Drug: ustekinumab
Sponsors: Centocor, Inc.; Centocor, Inc.
Recruiting - verified April 2012
Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)

Conditions: Brain Cancer; Glioblastoma
Interventions: Drug: Standard Dose Bevacizumab; Drug: Low Dose Bevacizumab; Drug: Lomustine
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer

Condition: Advanced Solid Tumors
Intervention: Drug: AMG 479, Everolimus, Panitumumab
Sponsors: Duke University; Duke University; Amgen; Novartis Pharmaceuticals
Recruiting - verified December 2011
HAI Abraxane With Gemcitabine and Bevacizumab

Condition: Advanced Cancers
Interventions: Drug: HAI Abraxane; Drug: Gemcitabine; Drug: Bevacizumab; Drug: Filgrastim
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Condition: Hairy Cell Leukemia
Interventions: Drug: Pentostatin; Drug: Rituximab; Drug: Bendamustine
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified August 2011
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

Condition: Sarcoma
Interventions: Biological: cixutumumab; Biological: dactinomycin; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: irinotecan hydrochloride; Drug: temozolomide; Drug: vincristine sulfate
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Safety and Efficacy of Investigational Immune Plasma in Treating Influenza A

Condition: Influenza A
Interventions: Biological: Anti-Influenza Plasma; Behavioral: Standard Care
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

Condition: Systemic Scleroderma
Interventions: Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: tacrolimus; Drug: mycophenolate mofetil; Biological: rituximab; Drug: cyclophosphamide; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Not yet recruiting - verified May 2012
Assessment of Small Bowel Healing in Crohn's Disease Patients Treated With Cimzia Using Wireless Capsule Endoscopy

Condition: Crohn's Disease
Intervention: Drug: certolizumab pegol
Sponsors: Shafran Gastroenterology Center; Shafran Gastroenterology Center; UCB, Inc.
Recruiting - verified July 2011
Monoclonal Antibody Ch14.18, Sargramostim, Aldesleukin, and Isotretinoin After Autologous Stem Cell Transplant in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin; Other: laboratory biomarker analysis
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified April 2011
RAD001, FOLFOX and Bevacizumab in Treatment of Colorectal Carcinoma

Condition: Colorectal Cancer
Interventions: Drug: RAD011; Drug: FOLFOX; Drug: Bevacizumab
Sponsors: University of Utah; University of Utah; Novartis
Recruiting - verified January 2012
Phase 2A Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer

Conditions: Metastatic Pancreatic Cancer; Metastatic Colorectal Cancer
Intervention: Drug: NPC-1C
Sponsors: Neogenix Oncology, Inc.; Neogenix Oncology, Inc.
Recruiting - verified January 2012
Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC

Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: Carboplatin; Drug: Pemetrexed; Drug: Panitumumab
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen
Recruiting - verified October 2011
Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy

Condition: Leukaemia, Lymphocytic, Chronic
Interventions: Biological: Ofatumumab; Other: No Intervention
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Eculizumab to Enable Renal Transplantation in Patients With History of Catastrophic Antiphospholipid Antibody Syndrome

Conditions: Antiphospholipid Antibody Syndrome; End Stage Renal Disease
Intervention: Drug: Eculizumab
Sponsors: Johns Hopkins University; Johns Hopkins University
Recruiting - verified August 2011
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Condition: Breast Cancer
Interventions: Drug: Panitumumab; Drug: Nab-paclitaxel; Drug: Carboplatin; Drug: 5-Fluorouracil; Drug: Epirubicin; Drug: Cyclophosphamide
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Celgene Corporation; Amgen
Recruiting - verified April 2012
A Study of a Human Anti-Intercellular Adhesion Molecule-1 Monoclonal Antibody, in Patients With Multiple Myeloma

Condition: Multiple Myeloma
Intervention: Biological: BI-505
Sponsors: BioInvent International AB; BioInvent International AB
Recruiting - verified January 2012
A Study of the Safety and Efficacy of CNTO 328 in Combination With Best Supportive Care Compared With Best Supportive Care in Patients With Multicentric Castleman's Disease

Condition: Castleman's Disease
Interventions: Drug: Placebo; Drug: CNTO 328
Sponsors: Janssen Research & Development, LLC; Janssen Research & Development, LLC
Recruiting - verified April 2012
Optimizing Cimzia in Crohn's Patients

Condition: Crohn's Disease
Interventions: Biological: certolizumab pegol; Biological: certolizumab pegol; Biological: certolizumab pegol; Biological: certolizumab pegol
Sponsors: Atlanta Gastroenterology Associates; Atlanta Gastroenterology Associates; UCB, Inc.
Recruiting - verified February 2012
Dasatinib, Bevacizumab, Paclitaxel in Patients With Advanced Malignancies

Condition: Advanced Cancer
Interventions: Drug: Dasatinib; Drug: Bevacizumab; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

Condition: Breast Cancer
Interventions: Biological: HER2Bi-armed activated T cells; Drug: Cyclophosphamide; Other: Laboratory biomarker analysis
Sponsors: Barbara Ann Karmanos Cancer Institute; Barbara Ann Karmanos Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified November 2011
A Dose Escalation Study of an Antibody in Patients With Advanced Cancers

Condition: Advanced Cancers
Intervention: Drug: MABp1
Sponsors: XBiotech, Inc.; XBiotech, Inc.
Recruiting - verified March 2012
Rituximab and Alemtuzumab in Treating Older Patients With Progressive Chronic Lymphocytic Leukemia

Condition: Leukemia
Interventions: Biological: alemtuzumab; Biological: rituximab
Sponsors: National Cancer Institute (NCI); Eastern Cooperative Oncology Group; National Cancer Institute (NCI)
Recruiting - verified February 2012
Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Conditions: Breast Cancer; Recurrent Breast Cancer; Stage IV Breast Cancer
Interventions: Biological: panitumumab; Drug: paclitaxel; Drug: carboplatin; Procedure: laboratory biomarker analysis; Procedure: immunohistochemistry staining method
Sponsors: Comprehensive Cancer Center of Wake Forest University; Comprehensive Cancer Center of Wake Forest University
Recruiting - verified April 2012
Cixutumumab and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer

Condition: Liver Cancer
Interventions: Biological: cixutumumab; Drug: sorafenib tosylate; Other: laboratory biomarker analysis
Sponsors: California Cancer Consortium; California Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Phase I Oncovir Poly IC:LC and NY-ESO-1/gp100/MART

Condition: Melanoma
Interventions: Drug: CP 870,893; Biological: Peptides; Biological: Oncovir poly IC:LC
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; H. Lee Moffitt Cancer Center and Research Institute; National Cancer Institute (NCI); Oncovir, Inc.; Pfizer
Recruiting - verified February 2012
ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Subjects With KRAS Wild-Type Metastatic Colorectal Cancer

Condition: Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab (Erbitux); Drug: Panitumumab (Vectibix)
Sponsors: Amgen; Amgen
Recruiting - verified May 2012
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Condition: High Risk Non-Hodgkin's Lymphoma
Interventions: Biological: Rituximab; Biological: Interleukin-2
Sponsors: Thomas Jefferson University; Thomas Jefferson University
Recruiting - verified April 2012
Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)

Conditions: Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
Intervention: Drug: Ofatumumab and Bendamustine
Sponsors: Georgetown University; Georgetown University; GlaxoSmithKline; Cephalon
Recruiting - verified October 2011
A Long-Term Safety And Tolerability Extension Study Of Bapineuzumab In Alzheimer Disease Patients

Condition: Alzheimer Disease
Intervention: Drug: Bapineuzumab 0.5 mg/kg
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant for Non-Hodgkin Lymphoma

Conditions: Anaplastic Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3 Follicular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult T-cell Leukemia/Lymphoma; Stage I Cutaneous T-cell Non-Hodgkin Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Mycosis Fungoides/Sezary Syndrome; Stage II Adult T-cell Leukemia/Lymphoma; Stage II Cutaneous T-cell Non-Hodgkin Lymphoma; Stage II Mycosis Fungoides/Sezary Syndrome; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult T-cell Leukemia/Lymphoma; Stage III Cutaneous T-cell Non-Hodgkin Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Mycosis Fungoides/Sezary Syndrome; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult T-cell Leukemia/Lymphoma; Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions: Drug: rituximab; Drug: carmustine; Drug: cytarabine; Drug: etoposide; Drug: melphalan; Drug: bortezomib; Drug: vorinostat; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung Cancer

Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: MM-121 (SAR256212) + erlotinib; Drug: Erlotinib
Sponsors: Merrimack Pharmaceuticals; Merrimack Pharmaceuticals; Sanofi-Aventis
Recruiting - verified January 2012
Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: milatuzumab; Biological: veltuzumab; Procedure: Correlative/Special Studies; Procedure: Quantitative T-, B-, and NK cell subsets; Procedure: Pharmacokinetics; Procedure: Pharmacokinetics; Procedure: Human Anti-Human Antibodies; Biological: veltuzumab and milatuzumab
Sponsors: Ohio State University Comprehensive Cancer Center; Beth Christian; Immunomedics, Inc.
Recruiting - verified May 2012
Donor Peripheral Blood Stem Cell Transplant and Pretargeted Radioimmunotherapy in Treating Patients With High-Risk Advanced Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia
Interventions: Biological: pretargeted radioimmunotherapy; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Radiation: total-body irradiation; Other: pharmacological study; Procedure: peripheral blood stem cell transplantation; Drug: fludarabine phosphate
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies

Condition: B-cell Malignancies
Intervention: Drug: MEDI-551
Sponsors: MedImmune LLC; MedImmune LLC
Recruiting - verified May 2012
HAI Irinotecan + IV Bevacizumab, Bevacizumab & Oxaliplatin or Bevacizumab & Cetuximab in Advanced Cancers Metastatic to Liver

Conditions: Liver Cancer; Advanced Cancer
Interventions: Drug: Irinotecan; Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified April 2012
Continued HER2 Suppression With Lapatinib Plus Trastuzumab Versus Trastuzumab Alone

Conditions: Adenocarcinoma; Her2+; Advanced Metastatic Breast Cancer; Metastatic ErbB2; Invasive Breast Cancer; Advanced Breast Cancer; Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsors: GlaxoSmithKline; GlaxoSmithKline
Recruiting - verified May 2012
Preoperative Treatment With Cetuximab and/or IMC-A12

Condition: Head and Neck Squamous Cell Carcinoma
Interventions: Drug: Cetuximab; Drug: IMC-A12; Procedure: Surgical tumor resection
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; ImClone LLC
Recruiting - verified February 2012
Blockage of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation

Condition: Multiple Myeloma
Interventions: Drug: CT-011; Biological: Dendritic Cell Fusion Vaccine
Sponsors: Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Dana-Farber Cancer Institute; Brigham and Women's Hospital; Rambam Health Care Campus; Gateway for Cancer Research; Department of Defense
Recruiting - verified January 2012
An SGN-35 Trial for Patients Who Have Previously Participated in an SGN-35 Study

Conditions: Disease, Hodgkin; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsors: Seattle Genetics, Inc.; Seattle Genetics, Inc.; Millennium Pharmaceuticals, Inc.
Recruiting - verified April 2012
Hepatic Arterial Infusion Oxaliplatin + 5FU, Leucovorin, and Bevacizumab +/- Cetuximab

Condition: Advanced Cancers
Interventions: Drug: HAI Oxaliplatin; Drug: 5-FU; Drug: Bevacizumab; Drug: Cetuximab; Drug: Leucovorin; Drug: 5-FU; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Horse ATG/CsA in Aplastic Anemia Patients Unresponsive to or With a Suboptimal Response to Rabbit ATG/CsA Treatment

Conditions: Anemia, Aplastic; Anemia, Hypoplastic
Interventions: Drug: h-ATG (ATGAM(Registered Trademark)); Drug: Cyclosporine (Gengraf(Registered Trademark))
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified April 2012
High-dose Chemotherapy for Poor-prognosis Relapsed Germ-Cell Tumors

Condition: Testicular Cancer
Interventions: Drug: Bevacizumab; Drug: Gemcitabine; Drug: Docetaxel; Drug: Melphalan; Drug: Carboplatin; Drug: Mesna; Drug: Ifosfamide; Drug: Etoposide; Procedure: Stem Cell Transplant
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified March 2012
Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Condition: Colorectal Cancer
Interventions: Biological: panitumumab; Drug: erlotinib hydrochloride; Drug: irinotecan hydrochloride
Sponsors: Northwestern University; Northwestern University; Genentech; OSI Pharmaceuticals; Amgen
Recruiting - verified July 2011
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Condition: Lymphocytic Leukemia
Interventions: Drug: alemtuzumab; Drug: everolimus
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified April 2012
Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

Condition: Adult T-Cell Leukemia (ATL)
Interventions: Drug: LMB-2; Drug: Fludarabine; Drug: Cyclophosphamide; Drug: LMB-2, anti-Tac(Fv)-PE38
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified April 2012
Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic

Conditions: B-cell Chronic Lymphocytic Leukemia; Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Biological: rituximab; Drug: vorinostat
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Treosulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders

Condition: Nonmalignant Neoplasm
Interventions: Procedure: umbilical cord blood transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: allogeneic bone marrow transplantation; Drug: fludarabine phosphate; Drug: treosulfan; Radiation: total-body irradiation; Drug: tacrolimus; Drug: methotrexate; Drug: cyclosporine; Drug: mycophenolate mofetil; Genetic: DNA analysis; Other: laboratory biomarker analysis; Genetic: cytogenetic analysis; Biological: anti-thymocyte globulin
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI); medac GmbH
Recruiting - verified April 2012
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors

Condition: Advanced Non-Hematologic Malignancies
Intervention: Drug: PF-04605412
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012
Peanut Oral Immunotherapy and Anti-Immunoglobulin E (IgE) for Peanut Allergy

Condition: Peanut Hypersensitivity
Interventions: Drug: Peanut Oral Immunotherapy; Drug: Omalizumab
Sponsors: Duke University; Duke University; Genentech
Recruiting - verified June 2011
A Study of Paclitaxel/Carboplatin With or Without IMC-3G3 in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Condition: Non-Small Cell Lung Cancer
Interventions: Biological: IMC-3G3; Drug: Paclitaxel; Drug: carboplatin
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified February 2012
Study of Natural Killer Cells in Bone Marrow and Blood Samples From Patients With and Without Hematologic Cancer

Conditions: Leukemia; Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Other: biologic sample preservation procedure; Other: immunologic technique; Other: laboratory biomarker analysis
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Study Evaluating The Long-Term Safety And Efficacy Of Subcutaneous Bapineuzumab

Condition: Alzheimer Disease
Intervention: Drug: bapineuzumab
Sponsors: Pfizer; Pfizer; JANSSEN Alzheimer Immunotherapy Research & Development, LLC
Recruiting - verified March 2012
A Study of IMC-A12 in Combination With Sorafenib in Patients With Advanced Cancer of the Liver

Condition: Hepatocellular Carcinoma
Interventions: Biological: IMC-A12 (cixutumumab); Biological: IMC-A12 (cixutumumab); Drug: sorafenib
Sponsors: ImClone LLC; ImClone LLC
Recruiting - verified October 2011
Biomarkers in Predicting Response to Tamoxifen and Letrozole in Postmenopausal Women With Primary Breast Cancer Treated on Clinical Trial CAN-NCIC-MA17

Condition: Breast Cancer
Interventions: Genetic: microarray analysis; Genetic: polymerase chain reaction; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: fluorescent antibody technique; Other: immunohistochemistry staining method; Other: immunologic technique
Sponsors: National Cancer Institute (NCI); Massachusetts General Hospital; National Cancer Institute (NCI)
Recruiting - verified April 2008
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme

Condition: Brain and Central Nervous System Tumors
Interventions: Biological: anti-PDGFR alpha monoclonal antibody IMC-3G3; Biological: ramucirumab
Sponsors: Sidney Kimmel Comprehensive Cancer Center; Sidney Kimmel Comprehensive Cancer Center; National Cancer Institute (NCI); ImClone LLC
Recruiting - verified April 2012
Study of Gemcitabine, Irinotecan and Panitumumab in Patients With Advanced and Metastatic Biliary Tract Adenocarcinoma

Conditions: Biliary Cancer; Cholangiocarcinoma
Intervention: Drug: Gemcitabine, Irinotecan, Panitumumab
Sponsors: University of Pennsylvania; University of Pennsylvania
Recruiting - verified December 2011
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer

Conditions: Non-melanomatous Skin Cancer; Pancreatic Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor
Interventions: Genetic: in situ hybridization; Genetic: protein expression analysis; Other: immunologic technique
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer

Condition: Metastatic Breast Cancer
Interventions: Drug: Panitumumab; Drug: Carboplatin; Drug: Gemcitabine
Sponsors: Sarah Cannon Research Institute; Sarah Cannon Research Institute; Amgen; Eli Lilly and Company
Recruiting - verified October 2011
Higher Infused Lymphocyte Counts Improve Antibody Response to Immunization After Autologous Stem Cell Transplantation

Condition: Lymphoma
Intervention:
Sponsors: Dartmouth-Hitchcock Medical Center; Dartmouth-Hitchcock Medical Center
Recruiting - verified January 2012
Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma

Conditions: Brain Cancer; Pediatric Cancers
Interventions: Drug: Bevacizumab; Drug: Lapatinib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; CERN Foundation - Collaborative Ependymoma Research Network
Recruiting - verified March 2012
Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain

Conditions: Lymphoma; Myeloma; Leukemia
Intervention: Biological: Genetically modified T cells
Sponsors: Baylor College of Medicine; Baylor College of Medicine; Texas Children's Hospital; The Methodist Hospital System; Center for Cell and Gene Therapy, Baylor College of Medicine
Recruiting - verified April 2012
Anti-TF Antibody (ALT-836) to Treat Septic Patients With Acute Lung Injury or Acute Respiratory Distress Syndrome

Conditions: Sepsis; Acute Lung Injury; Acute Respiratory Distress Syndrome
Interventions: Drug: ALT-836; Drug: Placebo
Sponsors: Altor Bioscience Corporation; Altor Bioscience Corporation; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2011
Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Conditions: Neuroblastoma; Bone Marrow, Sympathetic Nervous System
Intervention: Other: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center
Recruiting - verified November 2011
Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

Conditions: Recurrent Melanoma; Stage IV Melanoma
Interventions: Biological: ipilimumab; Drug: cyclophosphamide; Procedure: biopsy; Biological: aldesleukin; Other: immunohistochemistry staining method; Genetic: polymerase chain reaction; Other: immunoenzyme technique; Biological: therapeutic allogeneic cytotoxic T lymphocytes
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-Cell Lymphoma

Conditions: Childhood Diffuse Large Cell Lymphoma; Childhood Immunoblastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Childhood Grade III Lymphomatoid Granulomatosis; Recurrent Childhood Large Cell Lymphoma; Recurrent Childhood Lymphoblastic Lymphoma; Recurrent Childhood Small Noncleaved Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent/Refractory Childhood Hodgkin Lymphoma; Splenic Marginal Zone Lymphoma; Waldenström Macroglobulinemia
Interventions: Biological: rituximab; Genetic: polymorphism analysis; Other: pharmacological study; Other: laboratory biomarker analysis; Procedure: peripheral blood stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified March 2012
Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-cell Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified February 2012
Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

Condition: HIV Infections
Interventions: Biological: DNA plasmid vaccine; Biological: Recombinant adenoviral serotype 5 (rAD5) vector vaccine; Biological: DNA vaccine placebo; Biological: HIV-1 recombinant adenovirus vaccine placebo
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); National Institute of Allergy and Infectious Diseases (NIAID); HIV Vaccine Trials Network
Recruiting - verified May 2012
Evaluation of Persistence of Anti-meningococcal Bactericidal Antibodies Among Adolescents Who Previously Received MenACWY Conjugate Vaccine

Condition: Meningococcal Meningitis
Interventions: Other: Blood draw; Other: Blood draw; Other: Blood draw; Biological: Group IV; Biological: Group V
Sponsors: Novartis; Novartis Vaccines
Recruiting - verified May 2012
A Study of of MORAb-004 in Subjects With Solid Tumors

Condition: Solid Tumor
Intervention: Drug: MORAb-004 (monoclonal antibody to TEM1)
Sponsors: Morphotek; Morphotek
Recruiting - verified November 2011
Phase II Study of Irinotecan and Panitumumab

Condition: Esophageal Cancer
Interventions: Drug: Panitumumab; Drug: Irinotecan
Sponsors: University of Pittsburgh; University of Pittsburgh; Amgen
Recruiting - verified January 2012
Radioimmunoimaging of AL Amyloidosis

Condition: Primary Amyloidosis
Intervention: Biological: 124I-labeled monoclonal antibody Mu 11-1F4
Sponsors: University of Tennessee; University of Tennessee; FDA Office of Orphan Products Development
Recruiting - verified March 2012
Trial of Postoperative Radiation, Cisplatin, and Panitumumab in Locally Advanced Head and Neck Cancer

Condition: Head and Neck Cancer
Interventions: Drug: Panitumumab; Drug: Cisplatin; Radiation: Radiation Therapy
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified January 2012
Chemotherapeutic Agents in Brain/Breast

Conditions: Breast Cancer; Metastatic Cancer
Interventions: Drug: capecitabine; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: gemcitabine hydrochloride; Drug: lapatinib ditosylate; Drug: paclitaxel; Drug: vinorelbine ditartrate; Drug: Trastuzumab
Sponsors: Case Comprehensive Cancer Center; Case Comprehensive Cancer Center; Department of Defense; National Cancer Institute (NCI)
Recruiting - verified May 2012
Bevacizumab Plus Ipilimumab in Patients With Unresectable Stage III or IV Melanoma

Condition: Melanoma
Interventions: Drug: Bevacizumab Plus Ipilimumab; Drug: Bevacizumab Plus Ipilimumab; Drug: Bevacizumab Plus Ipilimumab; Drug: Bevacizumab Plus Ipilimumab
Sponsors: Dana-Farber Cancer Institute; Dana-Farber Cancer Institute; Genentech; Bristol-Myers Squibb
Recruiting - verified October 2011
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma

Condition: Choroidal Melanoma
Intervention: Drug: ranibizumab
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary; Genentech
Recruiting - verified January 2012
A Phase I Trial Of The Humanized Anti-GD2 Antibody In Children And Adolescents With Neuroblastoma Or Melanoma

Conditions: Neuroblastoma; Melanoma
Intervention: Biological: Anti-G2 antibody
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified January 2012
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy

Condition: Lung Cancer
Interventions: Other: high performance liquid chromatography; Other: pharmacological study; Procedure: radionuclide imaging; Procedure: single photon emission computed tomography; Radiation: radiation therapy; Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed By Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic Breast Cancer

Conditions: Estrogen Receptor-negative Breast Cancer; HER2-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage IV Breast Cancer; Triple-negative Breast Cancer
Interventions: Drug: paclitaxel albumin-stabilized nanoparticle formulation; Biological: bevacizumab; Drug: erlotinib hydrochloride; Other: immunohistochemistry staining method; Other: flow cytometry; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Multiple Ascending Dose (MDX1105-01)

Condition: Cancer, Multiple Indications
Interventions: Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody; Biological: Anti-PDL-1 antibody
Sponsors: Bristol-Myers Squibb; Bristol-Myers Squibb
Recruiting - verified May 2012
The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

Condition: Kidney Transplant
Intervention: Drug: Bortezomib
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified January 2012
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Conditions: Anaplastic Large Cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Marginal Zone Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia
Interventions: Biological: DI-Leu16-IL2 immunocytokine; Biological: rituximab; Other: flow cytometry; Other: immunohistochemistry staining method; Other: pharmacological study; Other: laboratory biomarker analysis; Other: enzyme-linked immunosorbent assay; Genetic: reverse transcriptase-polymerase chain reaction
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
The Use of Etanercept Enbrel as Sole Treatment for Grade I Acute Graft Versus Host Disease

Condition: Acute Graft Versus Host Disease
Intervention: Drug: Etanercept (Enbrel)
Sponsors: University of Michigan Cancer Center; University of Michigan Cancer Center
Recruiting - verified September 2011
Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy

Condition: Autoimmune Disorder
Interventions: Biological: anti-thymocyte globulin; Drug: carmustine; Drug: cytarabine; Drug: etoposide; Drug: melphalan; Drug: prednisone; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Procedure: syngeneic bone marrow transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified January 2012
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients

Conditions: Hepatitis B; Liver Transplantation
Intervention: Biological: HepaGam B
Sponsors: Cangene Corporation; Cangene Corporation
Recruiting - verified April 2012
A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors

Condition: Solid Tumor
Intervention: Drug: IMGN388
Sponsors: ImmunoGen, Inc.; ImmunoGen, Inc.
Recruiting - verified July 2011
Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Condition: Ovarian Neoplasms
Interventions: Drug: AMG 479; Drug: AMG 479 Placebo
Sponsors: Cancer International Research Group; Cancer International Research Group
Recruiting - verified March 2012
The Effect of TRA-8 on Ovarian Cancer Tissue

Condition: Ovarian Cancer
Intervention:
Sponsors: University of Alabama at Birmingham; University of Alabama at Birmingham
Recruiting - verified July 2011
Yttrium Y 90 Ibritumomab Tiuxetan With or Without Rituximab, Combination Chemotherapy, and an Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: carmustine; Drug: cytarabine; Drug: etoposide; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified April 2012
High-Dose Melphalan and Stem Cell Transplant in Treating Patients With Immunoglobulin Deposition Disease or Light-Chain Deposition Disease

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim; Drug: melphalan; Procedure: autologous hematopoietic stem cell transplantation
Sponsors: Boston Medical Center; Boston Medical Center
Recruiting - verified February 2012
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma

Conditions: Metastatic Melanoma; Cutaneous Melanoma
Interventions: Drug: Interferon alpha; Drug: KW2871; Drug: KW2871; Drug: interferon alpha; Drug: KW2871; Drug: Interferon alpha
Sponsors: Ludwig Institute for Cancer Research; Ludwig Institute for Cancer Research; Life Sciences Pharmaceuticals
Recruiting - verified April 2012
Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid Malignancies

Conditions: Leukemia; Myelodysplastic Syndrome
Intervention: Biological: ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195
Sponsors: Memorial Sloan-Kettering Cancer Center; Memorial Sloan-Kettering Cancer Center; National Cancer Institute (NCI); Actinium Pharmaceuticals
Recruiting - verified January 2012
A Study of Bevacizumab in Combination With Chemotherapy for Treatment of Osteosarcoma

Conditions: Osteosarcoma; Malignant Fibrous Histiocytoma (MFH) of Bone
Interventions: Biological: Bevacizumab; Drug: Chemotherapy (Cisplatin, Doxorubicin, Methotrexate, Ifosfamide, Etoposide)
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital; Genentech; National Institutes of Health (NIH)
Recruiting - verified June 2011
Dosing Regimen of Eculizumab Added to Conventional Treatment in Positive Cross Match Living Donor Kidney Transplant

Condition: Kidney Transplant
Intervention: Drug: Eculizumab
Sponsors: Mayo Clinic; Mark Stegall; Alexion Pharmaceuticals
Recruiting - verified December 2011
Study Evaluating The Efficacy And Safety Of Bapineuzumab In Alzheimer Disease Patients

Condition: Alzheimer Disease
Interventions: Drug: bapineuzumab; Drug: bapineuzumab; Drug: placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified April 2012
Panitumumab Pediatric Study

Condition: Solid Tumors
Intervention: Drug: Panitumumab Treatment
Sponsors: Amgen; Amgen
Recruiting - verified July 2011
Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery

Conditions: Liver Metastases; Recurrent Colon Cancer; Recurrent Rectal Cancer; Stage IV Colon Cancer; Stage IV Rectal Cancer
Interventions: Drug: gemcitabine hydrochloride; Drug: floxuridine; Genetic: proteomic profiling; Other: matrix-assisted laser desorption/ionization time of flight mass spectrometry; Other: liquid chromatography; Radiation: yttrium Y 90 anti-CEA monoclonal antibody cT84.66; Other: laboratory biomarker analysis; Other: mass spectrometry; Other: pharmacological study
Sponsors: City of Hope Medical Center; City of Hope Medical Center
Recruiting - verified March 2012
Intravenous Gammaglobulin for Sickle Cell Pain Crises

Condition: Sickle Cell Anemia
Intervention: Drug: Immune Globulin Intravenous
Sponsors: Shi, Patricia, M.D.; Shi, Patricia, M.D.; Grifols Therapeutics Inc.; Food and Drug Administration (FDA); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified September 2011
Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer

Condition: Pancreatic Cancer
Interventions: Drug: Bevacizumab; Drug: Erlotinib; Drug: Capecitabine; Radiation: Radiation Therapy
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center; Genentech
Recruiting - verified May 2012
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Solid Tumors That Did Not Respond to Treatment

Condition: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Biological: panitumumab; Drug: everolimus; Drug: fluorouracil; Drug: leucovorin calcium; Drug: oxaliplatin
Sponsors: UNC Lineberger Comprehensive Cancer Center; UNC Lineberger Comprehensive Cancer Center; National Cancer Institute (NCI)
Recruiting - verified February 2012
A-dmDT390-bisFv (UCHT1) Immunotoxin Therapy for Patients With T-cell Diseases

Conditions: T-cell Lymphomas; T-cell Leukemia; Sezary Syndrome; Mycosis Fungoides
Intervention: Biological: A-dmDT390-bisFv (UCHT1)
Sponsors: Scott and White Hospital & Clinic; Scott and White Hospital & Clinic; National Institute of Mental Health (NIMH)
Recruiting - verified February 2012
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome; Adult Acute Lymphoblastic Leukemia in Remission; Adult Acute Myeloid Leukemia in Remission; Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Chronic Myelomonocytic Leukemia; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Lymphoblastic Leukemia; Recurrent Adult Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Drug: fludarabine phosphate; Drug: cyclophosphamide; Radiation: total-body irradiation; Radiation: iodine I 131 monoclonal antibody BC8; Procedure: allogeneic bone marrow transplantation; Drug: tacrolimus; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Other: flow cytometry; Genetic: cytogenetic analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Condition: Lymphoma
Interventions: Biological: rituximab; Drug: bortezomib; Drug: carboplatin; Drug: dexamethasone; Drug: etoposide; Drug: ifosfamide; Genetic: polymerase chain reaction; Genetic: western blotting
Sponsors: AIDS Malignancy Clinical Trials Consortium; AIDS Malignancy Clinical Trials Consortium; National Cancer Institute (NCI)
Recruiting - verified December 2011
Yttrium Y 90 Ibritumomab Tiuxetan, Rituximab, Indium In-111 Ibritumomab Tiuxetan, Fludarabine, Melphalan, and Donor Stem Cell Transplant in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Conditions: Graft Versus Host Disease; Leukemia; Lymphoma
Interventions: Biological: rituximab; Drug: fludarabine phosphate; Drug: melphalan; Drug: sirolimus; Drug: tacrolimus; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Radiation: indium In 111 ibritumomab tiuxetan; Radiation: yttrium Y 90 ibritumomab tiuxetan
Sponsors: City of Hope Medical Center; City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting - verified May 2012
Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

Condition: Melanoma
Interventions: Drug: hu14.18-IL2; Drug: hu14.18-IL2
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; National Cancer Institute (NCI); EMD Serono
Recruiting - verified December 2011
Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors

Conditions: Leukemia; Solid Tumors
Interventions: Device: Clinimacs Cell Separation System; Drug: conditioning chemotherapy; Other: DLI
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison; Miltenyi Biotec GmbH
Recruiting - verified January 2012
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies

Conditions: Leukemia, Acute Lymphocytic (ALL); Leukemia, Myeloid, Acute(AML); Leukemia, Myeloid, Chronic(CML); Juvenile Myelomonocytic Leukemia (JMML); Hemoglobinuria, Paroxysmal Nocturnal (PNH); Hodgkin Lymphoma; Lymphoma, Non-Hodgkin (NHL); Myelodysplastic Syndrome (MDS)
Interventions: Device: CliniMACS; Procedure: Stem cell transplantation; Drug: Systemic chemotherapy and antibodies
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified April 2012
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed By a Donor Stem Cell Transplant in Treating Patients With Immunodeficiency or Other Nonmalignant Inherited Disorders

Condition: Precancerous Condition
Interventions: Biological: alemtuzumab; Drug: fludarabine phosphate; Radiation: low dose total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic bone marrow transplantation; Procedure: allogeneic hematopoietic cell transplantation; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Bevacizumab in Multiple Phase I Combinations

Condition: Advanced Cancer
Interventions: Drug: Bevacizumab; Drug: Sorafenib; Drug: Erlotinib; Drug: Trastuzumab; Drug: Lapatinib; Drug: Sunitinib; Drug: Cetuximab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Study of Veltuzumab (hA20) at Different Doses in Patients With ITP

Conditions: Purpura, Thrombocytopenic, Idiopathic; Autoimmune Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Autoimmune
Intervention: Biological: veltuzumab
Sponsors: Immunomedics, Inc.; Immunomedics, Inc.
Recruiting - verified January 2012
Valproic Acid and Bevacizumab in Patients With Advanced Cancer

Condition: Advanced Cancer
Interventions: Drug: Valproic Acid; Drug: Bevacizumab
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified February 2012
IGIV Study for Chronic ITP Patients Ages 3-70

Condition: Idiopathic Thrombocytopenic Purpura
Intervention: Biological: IGIV3I Grifols 10%
Sponsors: Grifols Biologicals Inc.; Grifols Biologicals Inc.
Recruiting - verified April 2012
Psoriasis Longitudinal Assessment and Registry (PSOLAR)

Conditions: Psoriasis; Arthritis, Psoriatic
Interventions: Biological: ustekinumab; Biological: Biological therapies other than infliximab and ustekinumab; Drug: conventional systemic agents; Biological: infliximab
Sponsors: Centocor Ortho Biotech Services, L.L.C.; Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified May 2012
Oxaliplatin and Paclitaxel Plus Bevacizumab in Advanced Peritoneal Carcinomatosis

Condition: Peritoneal Cancer
Interventions: Drug: Bevacizumab; Drug: Oxaliplatin; Drug: Paclitaxel
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome

Condition: Antiphospholipid Syndrome
Intervention:
Sponsors: Duke University; Duke University
Recruiting - verified August 2011
Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: rituximab; Drug: melphalan; Biological: Stem Cell; Biological: Sargramostim (GM-CSF); Radiation: 90Y-Zevalin; Biological: 111In Zevalin
Sponsors: Mayo Clinic; Mayo Clinic; National Cancer Institute (NCI)
Recruiting - verified May 2012
Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First Remission

Conditions: B-cell Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia
Interventions: Radiation: tositumomab and iodine I 131 tositumomab; Other: laboratory biomarker analysis
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified April 2012
Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy

Condition: Lymphoma
Interventions: Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone; Drug: Vincristine; Genetic: RNA-based gene array studies; Genetic: Real time PCR gene expression studies; Genetic: Tissue-array immunohistochemical studies; Genetic: Immunoglobulin G Fc receptor genotypes determination
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Condition: Lymphoma
Interventions: Drug: Rituximab; Drug: Ibritumomab Tiuxetan
Sponsors: University of Miami Sylvester Comprehensive Cancer Center; University of Miami Sylvester Comprehensive Cancer Center
Recruiting - verified March 2012
Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Conditions: Advanced Malignancy; Lymphoma; Myeloma; Solid Tumors
Interventions: Drug: Bevacizumab; Drug: Bortezomib
Sponsors: M.D. Anderson Cancer Center; M.D. Anderson Cancer Center
Recruiting - verified May 2012
Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Condition: Lymphoma
Interventions: Drug: rituximab; Drug: bortezomib; Drug: Ibritumomab tiuxetan
Sponsors: Northwestern University; Northwestern University; Robert H. Lurie Cancer Center
Recruiting - verified October 2011
Immune Responses to Antigens in Non-infectious Eye Inflammatory Diseases

Condition: Eye Diseases
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Eye Institute (NEI)
Recruiting - verified September 2011
E-Selectin Nasal Instillation to Prevent Secondary Stroke

Conditions: Ischemic Attack, Transient; Transient
Intervention: Drug: recombinant human E-selectin
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified June 2011
Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis

Condition: HTLV-1
Intervention: Drug: Hu MiK-Beta-1
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified August 2011
Alemtuzumab (Campath(Registered Trademark)) to Treat T-Large Granular Lymphocyte Leukemia

Condition: Lymphoproliferative Disorders
Intervention: Drug: Alemtuzumab (Campath)
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified February 2012
LMB-2 to Treat Hairy Cell Leukemia

Conditions: Positive Hairy Cell Leukemia; CD25-Expressing Hairy Cell Leukemia
Intervention: Biological: LMB-2
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

Conditions: Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes
Interventions: Biological: anti-thymocyte globulin; Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsors: Masonic Cancer Center, University of Minnesota; Masonic Cancer Center, University of Minnesota
Recruiting - verified December 2011
Rituximab&Methotrexate Chemotherapy w/BBBD & Sodium Thiosulfate Chemoprotection for Patients With Newly Diagnosed PCNSL

Conditions: Brain and Central Nervous System Tumors; Lymphoma
Interventions: Drug: Rituxan; Drug: Carboplatin; Drug: Methotrexate; Drug: Sodium thiosulfate; Drug: Neupogen; Drug: Neulasta; Drug: Leucovorin
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified January 2012
Studies of Disorders in Antibody Production and Related Primary Immunodeficiency States

Conditions: Hyper-IgM Syndrome; Ectodermal Dysplasia
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2012
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Neoplasms; Precancerous Condition
Interventions: Biological: therapeutic allogeneic lymphocytes; Drug: busulfan; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation; Radiation: Total Body Irradiation (TBI); Drug: Granulocyte colony-stimulating factor (G-CSF); Drug: Phenytoin; Drug: Methotrexate
Sponsors: OHSU Knight Cancer Institute; OHSU Knight Cancer Institute; National Cancer Institute (NCI)
Recruiting - verified March 2012
A Trial of Antenatal Treatment of Alloimmune Thrombocytopenia

Conditions: Alloimmune Thrombocytopenia; Fetal Alloimmune Thrombocytopenia
Intervention: Drug: IVIG (Intravenous Immunoglobulin)
Sponsors: Weill Medical College of Cornell University; Weill Medical College of Cornell University; New York Presbyterian Hospital; Columbia University
Recruiting - verified June 2011
Hepatitis C Virus and the Humoral Immune System

Condition: Hepatitis C Virus
Intervention:
Sponsors: Rockefeller University; Rockefeller University; National Institute of Allergy and Infectious Diseases (NIAID); New York Presbyterian Hospital
Recruiting - verified May 2012
A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome

Condition: Myelodysplastic Syndromes
Intervention: Drug: Alemtuzumab (Campath)
Sponsors: National Institutes of Health Clinical Center (CC); National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified January 2012
Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)

Conditions: Systemic Lupus Erythematosus; Antiphospholipid Syndrome
Intervention:
Sponsors: Hospital for Special Surgery, New York; Hospital for Special Surgery, New York; National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Recruiting - verified December 2011
HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

Conditions: Acute Myeloid Leukemia; Acute Lymphocytic Leukemia; Myelodysplasia; Chronic Myeloid Leukemia; Histiocytosis
Interventions: Drug: Chemotherapy and antibodies; Device: Miltenyi Biotec CliniMACS; Procedure: Allogeneic stem cell transplantation
Sponsors: St. Jude Children's Research Hospital; St. Jude Children's Research Hospital
Recruiting - verified December 2011
Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(15;17)(q22;q12); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Childhood Myelodysplastic Syndromes; Chronic Myelomonocytic Leukemia; Previously Treated Myelodysplastic Syndromes; Recurrent Adult Acute Myeloid Leukemia; Recurrent Childhood Acute Myeloid Leukemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Excess Blasts in Transformation; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndromes
Interventions: Radiation: iodine I 131 monoclonal antibody BC8; Drug: fludarabine phosphate; Radiation: total-body irradiation; Procedure: allogeneic hematopoietic stem cell transplantation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI)
Recruiting - verified January 2012
Monoclonal Antibody hA20 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Condition: Lymphoma
Intervention: Biological: veltuzumab
Sponsors: National Cancer Institute (NCI); Immunomedics, Inc.
Recruiting - verified May 2007
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions: B-cell Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma; T-cell Large Granular Lymphocyte Leukemia
Interventions: Biological: rituximab; Drug: fludarabine phosphate; Radiation: total-body irradiation; Drug: cyclosporine; Drug: mycophenolate mofetil; Procedure: allogeneic hematopoietic stem cell transplantation; Other: laboratory biomarker analysis; Procedure: peripheral blood stem cell transplantation
Sponsors: Fred Hutchinson Cancer Research Center; Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium; National Cancer Institute (NCI)
Recruiting - verified May 2012
Isotretinoin With or Without Monoclonal Antibody, Interleukin-2, and Sargramostim Following Stem Cell Transplantation in Treating Patients With Neuroblastoma

Condition: Neuroblastoma
Interventions: Biological: aldesleukin; Biological: monoclonal antibody Ch14.18; Biological: sargramostim; Drug: isotretinoin
Sponsors: National Cancer Institute (NCI); Children's Oncology Group; National Cancer Institute (NCI)
Recruiting - verified May 2012
Antibody Production in Immune Disorders

Condition: Immunologic Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified April 2012
Determination of Kidney Function

Condition: Kidney Disease
Intervention:
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified October 2011
Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia

Conditions: Cutaneous T Cell Lymphoma; Hodgkin's Disease; Neoplasm; Non Hodgkin's Lymphoma; Peripheral T Cell Lymphoma
Interventions: Drug: Y-90 Humanized Anti-Tac; Drug: Calcium-DTPA
Sponsors: National Institutes of Health Clinical Center (CC); National Cancer Institute (NCI)
Recruiting - verified July 2011